

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/127, 39/002, 39/02, 39/12, 39/29, 39/295, 39/385		A1	(11) International Publication Number: WO 95/22317 (43) International Publication Date: 24 August 1995 (24.08.95)
(21) International Application Number: PCT/US95/02121 (22) International Filing Date: 16 February 1995 (16.02.95) (30) Priority Data: 08/197,484 16 February 1994 (16.02.94) US		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(71) Applicant: CYTEL CORPORATION (US/US); 3525 John Hopkins Court, San Diego, CA 92121 (US) (72) Inventors: VITIELLO, Maria, A.; 7522 High Avenue, La Jolla, CA 92037 (US). CHESNUT, Robert, W.; 1473 Kings Cross Drive, Cardiff by the Sea, CA 92007 (US). SETTE, Alessandro, D.; 5551 Linda Rosa Avenue, La Jolla, CA 92037 (US). CELIS, Esteban; 13644 Landfair Road, San Diego, CA 92130 (US). GREY, Howard; 9066 La Jolla Shores Lane, La Jolla, CA 92037 (US). (74) Agents: PARMELEE, Steven, W. et al; Townsend and Townsend Khourie and Crew, Steuart Street Tower, 20th floor, One Market Plaza, San Francisco, CA 94105 (US).		Published <i>With international search report.</i>	
(54) Title: COMPOSITIONS AND METHODS FOR ELICITING CTL IMMUNITY			
(57) Abstract <p>Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions, of CTL-inducing peptide and an adjuvant or a lipidated peptide which induces a helper T cell (HTL) response stimulate the antigen specific CTL response. Among the viral antigens to which the CTL responses are effectively induced in humans are those of hepatitis B. The CTL response may be optimized by a regimen of two or more booster administrations. Cocktails of two or more CTL inducing peptides are employed to optimize epitope and/or MHC class I restricted coverage.</p>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BV	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

COMPOSITIONS AND METHODS FOR ELICITING CTL IMMUNITY

5

Related Applications

The present application is a continuation-in-part of U.S. Serial No. 07/935,811, filed August 26, 1992, which is a continuation-in-part of U.S. Serial No. 07/874,491, filed April 27, 1992 and now abandoned, which is a continuation-in-part of U.S. Serial No. 07/827,682, filed January 29, 1992 and now abandoned, which is a continuation-in-part of USSN 07/749,568, filed August 26, 1991 and now abandoned, each of which is incorporated herein by reference.

10

Background of the Invention

Cytotoxic T lymphocytes ("CTL") represent an important component of an animal's immune response against a variety of pathogens and cancers. CTL which have been specifically activated against a particular antigen are capable of killing the cell that contains or expresses the antigen. CTL are particularly important in providing an effective immune response against intracellular pathogens, such as a wide variety of viruses, and some bacteria and parasites. CTL responses are also believed to be capable of contributing to anti-tumor responses in afflicted or susceptible individuals.

The receptors on the surface of the CTL cannot recognize a foreign antigen directly, however. The CTL express an α - β heterodimeric T cell receptor which is capable of recognizing foreign antigen fragments bound to major histocompatibility complex (MHC) class I molecules on the surface of the effected (e.g., infected) cells. CTL also express the non-polymorphic CD8 antigen. This cell surface protein interacts with the third domain of the class I molecule on the antigen presenting cells

25

30

35

and plays a role in both stabilizing the interaction between the CTL and the antigen presenting cell and in CTL activation (Salter et al., Nature 345:41-46 (1990)).

There are a number of mechanisms by which CTL are thought to disrupt the infectious or tumorigenic process. Among these, one involves the production of lymphokines such as gamma interferon (IFN γ) and tumor necrosis factor alpha (TNFa), which are known to act directly on infected cells to inhibit viral replication (Gilles et al., J. Virol. 66:3955-3960 (1992)). In addition, IFN γ causes increased expression of MHC class I molecules on the surface of virus infected cells and enhances their ability to be recognized by CTL and trigger immune intervention (Hayata et al., Hepatology 13:1022-1028 (1991)).

A second mechanism by which CTL combat infections or tumors is through direct killing of the afflicted cell, e.g., those which are infected by the targeted virus (Cohen et al., Ann. Rev. Immunol. 10:267-293 (1992) and Henkart et al., Ann. Rev. Immunol. 3:31-58 (1985)). For example, since viruses must replicate within the host cell the lysis of infected cells destroys virus production prior to the liberation of infectious particles. The exact mechanism(s) by which CTL kill infected target cells remains unclear. Once CTL recognized an antigen presenting cell, close contact between the cells is established over a large surface area. A "direct hit" is then delivered by translocating enzymes present in cytoplasmic vacuoles of CTL to the antigen presenting cell, which enzymes kill the cell or perhaps induce programmed cell death, "apoptosis". Once CTL have delivered their "lethal hit" to the antigen presenting cells, they can detach and go on to kill other antigen presenting cells through repetition of the antigen-specific recognition, lymphokine release and target cell killing mechanisms.

The means by which CTL distinguish infected from non-infected cells is through the T cell receptor and its ability to specifically recognize a peptide fragment of viral protein that

is bound to the peptide-binding cleft of the MHC class I molecule (Monaco et al., Immunol. Today 13:173-179 (1992) and Townsend et al., Ann. Rev. Immunol. 7:601-624 (1989)). Several viral fragments that can serve as antigenic peptides have been identified.

The biochemical events that take place in the cytoplasm of infected cells leading to CTL recognition are termed antigen processing and presentation. While not completely defined, it seems clear that during the synthesis and assembly of the infecting viral or bacterial proteins, some proteolysis takes place in the cytoplasm (Monaco et al., Immunol. Today 13:173-179 (1992)). Structures called proteasomes cleave the foreign proteins into peptide fragments. These fragments are then transported into the endoplasmic reticulum (ER) by means of specific transporter proteins where newly synthesized MHC class I molecules are present. Those peptides that are capable of specifically binding to a given MHC class I molecule do so in the ER. The non-polymorphic class I β chain, β_2 microglobulin binds to the antigenic peptide-class I complex, thus forming a stable trimolecular complex that is transported to the cell surface and displayed as an integral membrane component.

The selection of which peptides bind to a particular MHC class I molecule is based on the ability of the peptide to bind within the binding pocket or cleft which resides at the outermost apex of the extra-cellular portion of the MHC molecule. For several MHC molecules, this peptide binding pocket has been precisely defined by X-ray crystallographic procedures allowing a visualization of the types and location of the chemical bonds that form to stabilize the interaction (Saper et al., J. Mol. Biol. 219:277-319 (1991)).

Because of the differences in the structure of the peptide binding pocket between the diverse set of histocompatibility alleles, e.g., the human HLA alleles, a distinct population of antigenic peptides is bound by each allele, although in some cases the population of antigenic

peptides may overlap for closely related alleles. Thus, the specificity of the CTL for a foreign antigen resides at the level of the ability of MHC class I molecules to bind to a specific peptide as well as for the T cell receptor on the CTL to recognize the foreign protein fragment bound to that specific MHC class I allele.

In animals, CD8+, MHC class I-restricted cytotoxic T cells play an important role in the immune mediated clearance of viral infections (e.g., Oldstone et al., Nature 321:239-243 (1986); Mackenzie et al., Immunol. 67:375 (1989); and Robertson et al., J. Virol. 66:3271-3277 (1992)). While similar studies have not been possible in humans, and thus direct proof is still lacking, all of the evidence points to a similar role for CTL.

The importance of CTL in viral clearance in animals is evidenced by lymphocytic choriomeningitis virus (LCMV) infection in mice (Oldstone et al., Nature 321:239-243 (1986); Mackenzie et al., Immunol. 67:375 (1989); Robertson et al., J. Virol. 66:3271-3277 (1992); and Ahmed et al., J. Virol. 61:3920-3929 (1987)). When LCMV infects newborns or immune-suppressed adult animals, they become chronically infected and virus is expressed in nearly all tissues of the body. In contrast, adult mice infected with LCMV mount a vigorous cellular and humoral response against the virus and clear the infection within one to two weeks. When chronic carriers of LCMV are adoptively treated by transfer of CD8+LCMV-specific, MHC class I-restricted CTL, the viral infection is cleared and the mice become resistant to subsequent LCMV challenge. Additional studies have shown that CTL are necessary and sufficient for LCMV clearance and that other aspects of the immune system need not be functioning (Oldstone et al., Nature 321:239-243 (1986) and Schulz et al. Proc. Natl. Acad. Sci. USA 88:991-993 (1991)).

In addition to mediating the clearance of virus from chronically infected animals, studies have demonstrated that CTL generated in vivo against a synthetic peptide which presents an antigenic epitope of LCMV are able to protect mice against acute

infection (Schulz et al., Proc. Natl. Acad. Sci. USA 88:991-993 (1991)). Mice injected with 100 μ g of a synthetic 15 amino acid peptide in complete Freund's adjuvant were fully protected from a lethal LCMV challenge.

With regard to the role of CTL in other viral infections, studies with influenza virus and respiratory syncytial virus in mice have similarly demonstrated the importance of CTL activation in the rapid and effective recovery from these infections.

Strong evidence from animal studies indicates that an acute infection can become chronic when there is an inadequate immune response to clear the infection (Ahmed, Concepts in Viral Pathogenesis III, Notkins and Oldstone eds., Springer-Verlag, New York, 304-310 (1989)). Once the chronic infection has been established, it appears to be more or less "tolerated" by the host's immune system. Tolerance appears to be organism-specific rather than a result of general immunosuppression (Fields et al., Fields Virology, Raven Press, New York, NY 2:2137-2236 (1990)). Studies examining which cells in the immune system are anergic or tolerant to the infecting organism suggest that the CD4+, class II-restricted T "helper" cells are dysfunctional (Schwartz, Cell 57:1073-1081 (1989)). Since class II-restricted T helper cells play a critical role in the initial priming of class I-restricted CTL (Cassell et al., Ann. NY Acad. Sci. 532:51-60 (1988) and Fayolle et al., J. Immunol. 174:4069 (1991)), diminished CD4 cell function may impair the capacity of the immune system to respond adequately, and may thus clear the way for chronic infection.

Decreased T helper cell activity has been shown in the case of chronic hepatitis B infection in humans, although the fact that some CD4+ T helper function is seen suggests that these cells are not completely dysfunctional (see, e.g., Ahmed et al., J. Virol. 61:3920-3929 (1987); Alberti et al., Lancet 1:1421-1424 (1988); Neurath et al., Nature 315:154-156 (1985); Celis et al., J. Immunol. 132:1511-1516 (1984); and Ferrari et

WO 95/22317

6

al., J. Immunol. 139:2050-2055 (1987)). Class I-restricted CTL can be detected in patients with chronic HBV infection (Barnaba et al., J. Immunol. 143:2650-2654 (1989)).

5 The requirement for lymphokines such as IL-2 in the generation of CD8+ CTL is well established, although the need for activation of CD4+ T helper cells to provide these lymphokines remains somewhat controversial. While the concept of linked T helper-B cell recognition for antibody production has been firmly defined, there is no compelling evidence for 10 linked T helper-CTL recognition for the in vivo induction of CD8+ CTL. See, e.g., Buller et al., Nature 328:77-79 (1987); Sarobe et al., Eur. J. Immunol. 21:1555-1558 (1991); and Cassell and Forman, Annals N.Y. Acad. Sci. :51-60 (1991).

15 Thus, the data available suggest that CD8+ class I-restricted cytotoxic T cells specific for foreign antigens such as viral proteins play a critical part in prevention of disease and clearance of an established disease process. Therefore, the challenge is to induce a sufficiently potent, antigen-specific, 20 cell-mediated immune response in humans and other mammals which, by itself or in conjunction with chemotherapeutic agents or the like, will either prevent a disease process such as an infection or tumor from becoming established, or will eliminate or at least ameliorate an infection or tumor which has already become 25 established in the host. Quite surprisingly, the present invention fulfills these and other related needs.

Summary of the Invention

30 The present invention provides compositions for inducing a cytotoxic T lymphocyte response to an antigen of interest in a mammal. The compositions comprise a peptide that induces a CTL response to the antigen and a peptide that induces a HTL response, wherein the HTL-inducing peptide is lipidated. The 35 HTL-inducing peptide is optionally linked to the CTL-inducing

peptide or not linked. When linked, the HTL-inducing peptide may be separated from the CTL peptide by a spacer, such as Ala-Ala-Ala. The HTL-inducing peptide will usually be linked at its C-terminal end to the CTL-inducing peptide. Typically, the lipid is linked to the N-terminus of the HTL-inducing peptide, where the linkage can optionally include a spacer, such as Lys-Ser-Ser or the like.

The antigen to which the cytotoxic T lymphocyte response is induced is selected from a viral, bacterial, parasitic or tumor antigen. Among the viral antigens to which the CTL responses are effectively induced are antigens of hepatitis B (such as envelope, core or polymerase antigens), hepatitis C or human papilloma virus. A particularly effective hepatitis B antigen is HBc18-27. Typically the CTL inducing peptide will be from seven to fifteen residues, and more usually from nine to eleven residues. The immunogenic composition can further comprise a carrier, such as physiologic saline, and an adjuvant, such as incomplete freunds adjuvant, alum or montanide. When the peptide is lipidated, it may be modified or unmodified. The lipid is preferably a linear alkyl chain of 6-22 carbons, and preferably is a linear alkyl chain of 16 carbons. In some embodiments of the present invention the lipid is comprised of palmitic acid attached to epsilon and alpha amino groups of a Lys residue, wherein the Lys is linked to the amino terminus of the HTL-inducing peptide by means of a linker.

In other embodiments the present invention comprises methods for inducing a cytotoxic T lymphocyte response in a mammal against an antigen such as a viral, bacterial, parasitic, or tumor antigen. The method comprises administering to the mammal a peptide that induces a CTL response to the antigen, and administering, either separately or together, a lipidated peptide that induces a HTL response. The HTL-inducing peptide is optionally linked to the CTL-inducing peptide or unlinked. When unlinked, the HTL-inducing peptide can be admixed with the CTL-inducing peptide. The HTL-inducing peptide and the

CTL-inducing peptide are typically administered to the mammal in a regimen of two or more administrations. These boosters are spaced a sufficient interval apart to optimize development of a CTL response to the antigen of interest, e.g., a second administration may be approximately four weeks after the initial administration. In representative embodiments described herein the antigen is hepatitis B antigen, such as HBc18-27 and the mammal is a human, of the HLA-A2.1 histocompatibility type for the HBc18-27 CTL inducing peptide.

10 In yet other embodiments the invention provides methods for treating or preventing a disease that is susceptible to treatment by a CTL response by administering a CTL-inducing peptide to an antigen associated with said disease, and a HTL-inducing peptide conjugated to a lipid. The induction of a CTL response can be used in the treatment or prevention of viral infection (e.g., hepatitis B, hepatitis C or human papilloma virus), bacterial or parasitic infection or tumors. When the disease is hepatitis B infection, for example, the methods can be used to treat or prevent chronic or acute infection.

15 20 In yet other embodiments the invention provides methods for inducing a cytotoxic T lymphocyte response in a human against an antigen of interest. The methods comprise administering a composition which comprises a peptide that induces a CTL response to said antigen in a human and an adjuvant. The method may further comprise administering a peptide that induces a HTL response, and in some embodiments the HTL inducing peptide is linked to the CTL inducing peptide.

25 30 In other aspects the invention provides methods for inducing a CTL response in a human against an antigen of interest by administering a peptide that induces a CTL response to the antigen and a peptide that induces a HTL response, where the CTL inducing and/or the HTL inducing peptide is lipidated. The CTL and HTL inducing peptides may be linked or unlinked. The HTL inducing peptide is preferably lipidated. The lipidated HTL inducing peptide can be combined with a cocktail of at least

two CTL inducing peptides to optimize coverage of individuals of different HLA types or, in some instances, different antigen strains.

In a further aspect of the invention methods are described for inducing an effective CTL response in a human against an antigen of interest. According to these methods one or more peptides that induce a CTL response to the antigen, such as a viral, bacterial, parasitic or tumor antigen, is administered to a human together or separately with a peptide that induces a HTL response, where at least the CTL inducing and/or the HTL inducing peptide is lipidated. In representative embodiments of such a method described herein the CTL response is induced is to a viral antigen, such as hepatitis B antigen.

Pharmaceutical composition for the treatment of hepatitis B infection are also provided. These compositions comprise a peptide that induces a CTL response to hepatitis B and a peptide that induces a HTL response, where the HTL-inducing peptide is conjugated to a lipid, together with a pharmaceutically acceptable carrier. The carrier can be a liposome, for example, and the pharmaceutical composition may further comprises an adjuvant, such as incomplete Freund's adjuvant, alum or montanide.

Brief Description of the Drawings

Fig. 1 depicts the results of induction of HBV peptide-specific A2.1-restricted CTL by priming A2.1/K^b transgenic mice with syngeneic spleen cells "loaded" with HBV. Panels A-D: Splenocytes from HBV-primed transgenic mice were restimulated in vitro with four mixtures of syngeneic LPS blasts each coated with one of 13 different peptides. After 9 days effector cells were assayed for lytic activity against ⁵¹Cr labelled Jurkat A2.1/K^b target cells in the presence or absence of the four different peptide mixtures used for induction. Panels E-M:

Effector cells raised against the four different peptide mixtures were restimulated in vitro against the same peptide mixtures and assayed for lytic activity against ^{51}Cr labelled Jurkat A2.1/K^b target cells in the presence or absence of the individual peptides.

Fig. 2 illustrates the HBV peptide specificity of A2.1 transgenic CTL. Transgenic CTL raised from HBV-primed transgenic mice and restimulated in vitro twice with one of the four different peptide mixtures were restimulated with individual HBV peptides and assayed for lytic activity on ^{51}Cr labelled Jurkat target cells in the presence or absence of the HBV peptides used for the restimulation.

Fig. 3 illustrates the results of induction of HBV peptide-specific A2.1-restricted CTL by priming A2.1/K^b transgenic mice with HBV in IFA. A. Splenocytes from HBV-primed transgenic mice were restimulated in vitro with syngeneic LPS blasts coated with HBV peptides. After 6d, effector cells were assayed for lytic activity against ^{51}Cr labelled Jurkat A2.1/K^b target cells in the presence or absence of the appropriate HBV peptide. Each panel represents the CTL activity induced by the indicated target peptide.

Fig 4. The effector CTL of Fig. 3 were restimulated with peptide coated LPS blasts followed at a one week interval by restimulation with peptide coated Jurkat A2.1/K^b cells. Six days after the last restimulation, effector cells were assayed for cytolytic activity against ^{51}Cr labelled Jurkat A2.1/K^b target cells in the absence or presence of the peptide used for the restimulation, plus related peptides. Each panel represents the CTL activity induced by the peptide indicated in the corresponding panel of Fig. 3. The target peptides are indicated in each panel.

Fig. 5 illustrates that no HBc18-27-specific CTL response is detected in mice primed with the HBc 875.23 T helper epitope alone. Animals were primed subcutaneously with 100 μg of 875.23 (T helper epitope) in Complete Freund's Adjuvant (CFA)

followed 9 days later (subcutaneously) with IFA alone. Splenocytes were removed 3 weeks later, cultured for 6 days in the presence of LPS- blasts that had been incubated with the CTL epitope (875.15), 100 μ g for 2 hrs before being washed and added to the culture as a source of antigen presenting cells. The presence of HBc 18-27 (875.15)-specific CTL was determined using a standard 6 hr 15 Cr release assay with Jurkat A2.1/K^b cells as targets.

Fig. 6 illustrates that no HBc 18-27-specific CTL response was detected when mice were primed with HBc18-27 (875.15) in IFA. Experimental protocol was similar to that described in Fig. 5, except that mice received 100 μ g of peptide 875.15 subcutaneously in IFA rather than IFA alone for in vivo CTL priming.

Fig. 7 illustrates that HBc18-27-specific CTL response was detected in 50% of the mice primed with HBc T helper peptide (875.23) mixed with HBc CTL inducing peptide (875.15) at a 1 to 1 ratio. The experimental protocol was similar to that described in Figs. 5 and 6.

Fig. 8 illustrates that HBc-specific (875.15) CTL activity was detected in mice primed with peptide 902.01 in which the HBc T helper and CTL inducing peptide were linked via a peptide bond. Experimental protocol was similar to that in Figs. 5 and 6.

Fig. 9 illustrates that the greatest HBc18-27 (875.15)-specific CTL activity was detected in mice primed with peptide 902.02 in which the HBc T helper and CTL epitopes were linked via peptide bonds using an exemplary spacer such as alanine-alanine-alanine. Protocol was similar to that in Figs. 5 and 6.

Fig. 10 illustrates that previous priming of helper T cells was not required for in vivo priming of HBc 18-27-specific CTL responses using peptide 902.01 and 902.02. CTL response is shown from animals primed subcutaneously with peptide 902.01 (Fig. 10A) or 902.02 (Fig. 10B) alone without the previous priming with peptide 875.23 in CFA.

Fig. 11 illustrates the induction of HBenv₃₆₀₋₃₆₈ specific CTL response. A2.K^b transgenic mice were injected with 100 microliters of an emulsion (IFA) of 100 mg HBenv360-368 and 100 mg HBc128-140. Three weeks later, splenocytes were restimulated with syngeneic LPS blasts coated with peptide HBenv360-368. Effector cells were assayed for cytotoxicity against ⁵¹Cr labeled Jurkat A2/K^b target cells in the presence or absence of HBenv 360-368.

Fig. 12 illustrates the induction of a CTL response specific for HBc 18-27 by priming with a peptide containing HBc 18-27 linked to tetanus toxoid 830-843 (human helper T cell epitope). Effector cells were assayed against ⁵¹Cr labeled Jurkat A2-1/K^b target cells in the present or absence of HBc 18-27; Jy target cells in the presence or absence of HBc 18-27 and Jy cells that had been transfected with HBV core.

Fig. 13 illustrates the minimal sequence for CTL recognition within HBV env 329-348 peptide (799.09). CTL lines 110 and 113 were derived from splenocytes obtained from A2K^b transgenic mice primed subcutaneously with HBV virus in IFA and in vitro activated with 799.09 coated stimulator cells. 799.09 specific CTL lines 110 and 113 were assayed for lytic activity in a 6 hr ⁵¹Cr release assay using JA2K^b cells as targets in the presence of 799.09 peptide truncations (Panel A = 799.09 N-terminus truncations; Panel B = 799.09 overlapping 9 mers and 10 mers).

Fig. 14 shows the HBc18-27 specific CTL response (d7 assay) from subjects immunized with placebo or CY-1899. The CTL response against HBc18-27 was assessed by culturing 4 x 10⁶ PBMC/well in 24 well plates in the presence of HBc18-27 peptide. On day three and 6 after initiation cultures were fed with 10 U/ml IL-2 (final concentration). On day 7, part of the wells (2-3) were harvested and CTL activity was measured using ⁵¹Cr-labeled .221 A₂ target cells in the absence or presence of HBc18-27 peptide and in the presence of a 20 fold excess of K562 cells (K562 cells were added in order to decrease background

WO 95/22317

13

lysis caused by NK cells). The data are expressed in lytic units/ 10^6 cells were one lytic unit is defined as the number of lymphocytes required to achieve 30% lysis of 10000 .221 A₂ during a 6 hour assay. Each bar represents the specific CTL activity (i.e. in the present of peptide - in the absence of peptide).

Fig. 15 shows the HBc18-27 specific CTL response (d14 assay) from subjects immunized with placebo or CY-1899. On day 7 after initiation of cultures (see Fig. 1), the remaining wells (2-3) were harvested and cells were restimulated with HBc18-27 peptide-coated autologous adherent cells. Cultures were fed with 10 U/ml IL-2 on day 9 and thereafter as needed. CTL activity was assayed on d14 using the procedure described in Fig. 1.

Fig. 16 shows the mean and standard deviation of peak CTL activity: the mean and standard deviation of peak CTL activity after the first and second injections of different doses of CY-1899.

Fig. 17 shows HBc18-27 specific CTL from subjects injected with CY-1899 recognize endogenous processed antigen. Effector CTL obtained from subjects 302 and 304 after 14 days of culture were restimulated as described in Fig. 2 CTL activity was assayed 7 days later as described in Fig. 1 using as targets .221 A₂ cells in the absence (--) or presence (---) of HBc18-27 peptide and .221 A₂ cells transfected with the HBV core protein (-Δ-).

Fig. 18 shows the proliferation response to T cells specific for the TT 830-843 helper peptide from subjects immunized with placebo or CY-1899. T cell proliferation response against the helper peptide epitope was measured by culturing 1.5×10^5 PBMC from each sample in flat-bottom 96/plate wells with or without 10 µg/ml TT peptide. Seven days later, cultures were fed with medium containing recombinant IL-2 (20 U/ml final concentration) to induce further proliferation of T cells which had been stimulated against the peptide. On day 9

after initiation of culture, 1 μ Cl of 3 H-thymidine was added to each well and 18 hr. later, cells in each well were harvested onto glass fiber mats and counted for 3 H-thymidine incorporation into DNA. Each bar represents the difference in cpm 3 H-thymidine incorporation obtained from wells which received peptide minus those which did not receive peptide.

5

Description of the Specific Embodiments

10

The present invention provides compositions and methods for inducing an effective CTL-mediated response to an antigen of interest in humans and other mammals. The composition is comprised of peptides that are capable of inducing MHC class I-restricted CTL responses to the antigen of interest ("CTL peptide") and an adjuvant. Another embodiment to the present invention is directed to a composition comprised of said CTL peptide and a peptide capable of eliciting a helper T lymphocyte (HTL) response. Another embodiment of the invention is directed to either or both the CTL and HTL peptide by lipidated, linked or unlinked and administered with or without an adjuvant preparation. In particularly preferred embodiments either the CTL peptide or the HTL peptide is lipidated, linked or unlinked and administered without an adjuvant. In a preferred embodiment the HTL epitope is lipidated and linked to the CTL epitope and administered without an adjuvant. In another preferred embodiment the lipidated HTL peptide is admixed with, but not linked to, at least one CTL peptide.

15

20

25

30

35

By administering the compositions of the present invention an effective CTL response is stimulated in the recipient mammal to the antigen of interest. The cells which are targeted by the CTL response can be involved in a wide variety of disease or potential disease states, e.g., cells which are infected by viruses, bacteria or parasites, cells which express certain tumor antigens, and cells which express autoimmune antigens or other antigens that are capable of being

recognized as self by the mammal's CTL. The specifically stimulated CTL attack the target cells by secreting lymphokines (e.g., gamma interferon) and liberating products (e.g., proteolytic enzymes such as serine esterases) that inhibit replication of the infecting organism in the cells and/or kill the cells which express the antigen of interest, and thus are able to interrupt or substantially prevent the disease of interest, e.g., a viral infection, parasite or bacterial infection, a tumor or an autoimmune disease process.

The CTL inducing peptides which are useful in the compositions and methods of the present invention can be selected from a variety of sources, depending of course on the targeted antigen of interest. The CTL inducing peptides are typically small peptides that are derived from selected epitopic regions of target antigens associated with an effective CTL response to the disease of interest. Thus, by "CTL inducing peptide" or "CTL peptide" of the present invention is meant a chain of at least four amino acid residues, preferably at least six, more preferably eight to ten, sometimes eleven to fourteen residues, and usually fewer than about thirty residues, more usually fewer than about twenty-five, and preferably fewer than fifteen, e.g., eight to fourteen amino acid residues derived from selected epitopic regions of the target antigen(s).

25 Peptides that induce CTL responses are used in the methods and compositions of the present invention irrespective of the method or methods used to identify the epitope recognized by CTL. The CTL epitope(s) contained in the CTL peptides can be identified in one of several ways. In those cases where antigen-specific CTL lines or clones are available, for example tumor-infiltrating lymphocytes (TIL) or virus-specific CTL, 30 these cells can be used to screen for the presence of the relevant epitopes using target cells prepared with specific antigens. Such targets can be prepared using random, or selected synthetic peptide libraries, which would be utilized to 35 sensitize the target cells for lysis by the CTL. Another

approach to identify the relevant CTL epitope when CTL are available is to use recombinant DNA methodologies. Gene, or preferably cDNA, libraries from CTL-susceptible targets are first prepared and transfected into non-susceptible target cells. This allows the identification and cloning of the gene coding the protein precursor to the peptide containing the CTL epitope. The second step in this process is to prepare truncated genes from the relevant cloned gene, in order to narrow down the region that encodes for the CTL epitope. This step is optional if the gene is not too large. The third step is to prepare synthetic peptides of approximately 10-20 amino acids of length, overlapping by 5 residues, which are used to sensitize targets for the CTL. When a peptide, or peptides, are shown to contain the relevant CTL epitope, smaller peptides can be prepared to establish the peptide of minimal size that contains the CTL epitope. These epitopes are usually contained within 9-10 residues. Examples of peptides containing known CTL epitopes identified in this way are listed below.

ANTIGEN SOURCE	SEQUENCE	SEQ. ID NO.	HLA-RESTRICTION
MAGE-1	EADPTGHSY	1	A1
HIV nef84-94	AVDLSHFLK	2	A11
EBNA4 416-424	IVTDFSVIK	3	A11
HBC18-27	FLPSDFFPSV	4	A2.1
HIV RT	ILKEPVHGV	5	A2.1
HTLV-1, Tox 12-19	LPGYPVYV	6	A2.1
Influenza A, M1 58-66	GILGFVFTL	7	A2.1
HCMV, gB 619-628	IAGNNSAYEYV	8	A2.1
p53 264-272 A8	LLGRNSFEV	9	A2.1
HBVadr-ENV (S Ag335-343)	WLSLLVPPFV	10	A2.1
c-ErbB2 (HER-2/neu)	RFRELVSEFSRMARDPQ	11	A2.1
HIV nef73-82	QVPLRPMTYK	12	A3, A11
HIV-1 NL43 env gp41768-778	RLRDLILLIVTR	13	A3.1
HCV 141-151	STLPETTVVRR	14	A31 Aw68
NP 383-391	SRYWAIRTR	15	B27
HIV gag p24 265-274	KRWIILGLNK	16	B27
P.falciparum circumsp. 368-375	KPKDELDY	17	B35
P.falciparum circumsp. 368-375	KSKDLEDY	18	B35
P.falciparum liverAg1850-1857	KPNDKSLY	19	B35
HIV-2	TPYDINQML	20	B53
P.falciparum liverAg1786-1794	KPIVQYDNP	21	B53
B53 self peptide	YPAEITLTW	22	B53
HIV gp41 586-593	YLKDQQLL	23	B8
NP 380-388	ELRSRYWAI	24	B8
EBV EBNA-3	FLRGRAYGI	25	B8
HIV gag261-269	GEIYKRWII	26	B8
HIV gag331-339	DCKTILKAL	27	B8
HIV pol185-193	DPKVQWPL	28	B8
HIV gp41 586-593	YLKDQQQLYL	29	B8
HIV gap p17.3	GGKKKYKLK	30	B8

Another way of identifying a peptide containing a CTL epitope, when CTLs are present, is to elute the peptide with an acid or base. The peptides associated with MHC molecules are present

on the cells that are lysed by the CTL. The eluted peptides are separated using a purification method such as HPLC, and individual fractions are tested for their capacity to sensitize targets for CTL lysis. When a fraction has been identified as containing the CTL peptide, it is further purified and submitted to sequence analysis. The peptide sequence can also be determined using tandem mass spectrometry. A synthetic peptide is then prepared and tested with the CTL to corroborate that the correct sequence and peptide have been identified.

In some circumstances, where CTL are not available there are other means to identify potential CTL epitopes. These methods rely in the identification of MHC-binding peptides from known protein sequences. These methods have been described in detail in pending patent applications (U.S. Patent Applications Serial Nos. 08/159,339, 08/073,205 and EPO Patent Application No. 92201252.1, which are herein incorporated by reference). Briefly, the protein sequences for example from viral or tumor cell components are examined for the presence of MHC-binding motifs. These binding motifs which exist for each MHC allele, are conserved amino acid residues, usually at positions 2 (or 3) and 9 (or 10) in peptides of 9-10 residues long. Synthetic peptides are then prepared of those sequences bearing the MHC binding motifs, and subsequently are tested for their ability to bind to MHC molecules. The MHC binding assay can be done either using cells which express high number of empty MHC molecules (cellular binding assay), or using purified MHC molecules. Lastly, the MHC binding peptides are then tested for their capacity to induce a CTL response in naive individuals, either in vitro using human lymphocytes, or in vivo using HLA-transgenic animals. These CTL are tested using peptide-sensitized target cells, and targets that naturally process the antigen, such as viral infected cells or tumor cells. For example, a HLA-A1-restricted CTL epitope for the tumor-associated antigen MAGE-3 has been identified using this approach and is the subject of a pending patent application

(U.S. patent application Serial No. 08/186,266, which is herein incorporated by reference.

Desirably, the CTL peptide will be as small as possible while still maintaining substantially all of the biological activity of a larger peptide. When possible, it may be desirable to optimize peptides of the invention to a length of eight to twelve amino acid residues, more usually nine or ten amino acid residues, commensurate in size with endogenously processed antigen peptide that is bound to MHC class I molecules on the cell surface. See generally, 5 Schumacher et al., Nature 350:703-706 (1991); Van Bleek et al., Nature 348:213-216 (1990); Rotzschke et al., Nature 348:252-254 (1990); and Falk et al., Nature 351:290-296 (1991), which are incorporated herein by reference. By 10 biological activity of a CTL inducing peptide is meant the ability to bind an appropriate MHC molecule and, in the case of peptides useful for stimulating CTL responses, induce a CTL response against the selected antigen or antigen mimetic. By 15 a CTL response is meant a CD8⁺ T lymphocyte response specific for an antigen of interest, wherein CD8⁺, MHC class I- 20 restricted T lymphocytes are activated. As noted above, the activated cytotoxic T lymphocytes will secrete a variety of products which inhibit and may or may not kill the targeted cell.

25 The compositions and methods of the present invention are particularly preferred for targeting host cells infected by viruses. CTL responses are an important component of the immune responses of most mammals to a wide variety of viruses, and the present invention provides a means to effectively 30 stimulate a CTL response to virus-infected cells and treat or prevent such an infection in a host mammal. Thus the compositions and methods of the present invention are applicable to any virus presenting protein and/or peptide 35 antigens. Such viruses include but are not limited to the following, pathogenic viruses such as influenza A and B viruses (FLU-A, FLU-B), human immunodeficiency type I and II viruses (HIV-I, HIV-II), Epstein-Barr virus (EBV), human T

lymphotropic (or T-cell leukemia) virus type I and type II (HTLV-I, HTLV-II), human papillomaviruses types 1 to 18 (HPV-1 to HPV-18), rubella (RV), varicella-zoster (VZV), hepatitis B (HBV), hepatitis C (HCV), adenoviruses (AV), and herpes simplex viruses (HV). In addition, cytomegalovirus (CMV), 5 poliovirus, respiratory syncytial (RSV), rhinovirus, rabies, mumps, rotavirus and measles viruses.

In a like manner, the compositions and methods of the present invention are applicable to tumor-associated proteins, 10 which could be sources for CTL epitopes. Such tumor proteins and/or peptides, include, but are not limited to, products of the MAGE-1, -2 and -3 genes, products of the c-ErbB2 (HER-2/neu) proto-oncogene, tumor suppressor and regulatory genes which could be either mutated or overexpressed such as p53, 15 ras, myc, and RB1. Tissue specific proteins to target CTL responses to tumors such as prostatic specific antigen (PSA) and prostatic acid phosphatase (PAP) for prostate cancer, and tyrosinase for melanoma. In addition viral related proteins associated with cell transformation into tumor cells such as 20 EBNA-1, HPV E6 and E7 are likewise applicable. A large number of peptides from some of the above proteins have been identified for the presence of MHC-binding motifs and for 25 their ability to bind with high efficiency to purified MHC molecules and are the subject of pending patent applications (U.S. patent application Serial Nos. 08/159,339 and 08/073,205, previously incorporated herein by reference).

The peptides can be prepared "synthetically," as described hereinbelow, or by recombinant DNA technology. 30 Although the peptide will preferably be substantially free of other naturally occurring viral, bacterial, parasitic, tumor or self proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments or particles. The term peptide is used 35 interchangeably with polypeptide in the present specification to designate a series of amino acids connected one to the other by peptide bonds between the alpha-amino and alpha-carboxy groups of adjacent amino acids. The polypeptides or

peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

The terms "homologous", "substantially homologous", and "substantial homology" as used herein denote a sequence of amino acids having at least 50% identity wherein one sequence is compared to a reference sequence of amino acids. The percentage of sequence identity or homology is calculated by comparing one to another when aligned to corresponding portions of the reference sequence.

The peptides useful in the present invention can be optionally flanked and/or modified at one or both of the N- and C-termini, as desired, by amino acids from the naturally occurring (e.g., HBV) sequences, amino acids added to facilitate linking to another peptide or to a lipid, other N- and C-terminal modifications, linked to carriers, etc., as further described herein. Additional amino acids can be added to the termini of a peptide to provide for modifying the physical or chemical properties of the peptide or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N- terminus of the peptide or oligopeptide. In addition, the peptide sequences can differ from the natural sequence by being modified by terminal-NH₂ acylation, e.g., by alkanoyl (C₁-C₂₀) or thioglycolyl acetylation, terminal-carboxy amidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

It will be understood that the peptides of the present invention or analogs thereof which have CTL stimulating activity may be modified to provide other desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide. For instance,

the peptides can be modified by extending, decreasing or substituting in the peptides amino acid sequences by, e.g., the addition or deletion of amino acids on either the amino terminal or carboxy terminal end, or both, of peptides derived from the sequences disclosed herein.

With respect to treatment or prevention of hepatitis B infection in humans, selection of a CTL inducing peptide(s) useful in the present invention can be as set forth in more detail in copending applications U.S. Serial Nos. 07/935,811, 10 07/935,898 and 08/024,120 which are incorporated herein by reference. These applications provide the ability to select one or more peptides that induce CTL response to a hepatitis B antigen, which response is capable of killing (or inhibiting) cells which are infected by or otherwise express (in the case of transfected cells) the native HBV antigens. The HBV CTL inducing peptide will usually have at least four, sometimes six, often seven or more residues, or a majority of amino acids of that peptide, that are identical or homologous when compared to the corresponding portion of the naturally occurring HBV sequence. For example, those peptides which are preferred for stimulating HBV CTL responses include

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HBV POL	1117	LIAQFTSAI	9	31	9.6000
HBV ENV	338	LLVPPVQWPV	10	32	1.6000
HBV ENV	335	WLSLLVPFV	9	33	0.9600
HBV ENV	1116	PLLAQFTSA	9	34	0.6600
HBV POL	1147	PLLSLGIHL	9	35	0.5200
HBV POL	1245	ALMLPLYACI	9	36	0.5000
HBV ENV	249	ILLLCLIFL	10	37	0.3000
HBV POL	1092	KLHLVYSHPI	9	38	0.2900
HBV ENV	259	VLLDYQGML	9	39	0.1100
HBV ENV	378	LLPIFFCLWV	10	40	0.1000
HBV ENV	177	VLQAGFFLL	9	41	0.0660
HBV POL	721	YLHTLWKAGI	10	42	0.0560
HBV POL	721	YLHTLWKAGV	10	43	0.1300
HBV ENV	377	PLLPIFFCL	9	44	0.0310
HBV NUC (CORE)	529	ILSTLPETTV	10	45	0.0220

Other HBV CTL stimulating peptides include HBenv₃₀₉₋₃₂₈ (peptide 799.08), HBenv₃₂₉₋₃₄₉ (peptide 799.09) or HBenv₃₄₉₋₃₆₈ (peptide 799.10), and the HBC region HBC₉₁₋₁₁₀ (peptide 802.03).

For example, a CTL inducing HBC peptide comprises from six to thirty amino acids and is derived from the region HBC₁₈₋₂₇, contains at least one CTL epitopic site, and has at least seven amino acids wherein a majority of amino acids of the peptide will be identical or substantially homologous, when compared to the amino acids comprising the corresponding portion of the naturally occurring HBC₁₈₋₂₇ sequence. A representative peptide of this region is peptide HBC₁₈₋₂₇, which has the following sequence (for HBV subtype ayw):

HBC₁₈₋₂₇ - [Seq. ID No. 4]

FLPSDFFPSV

With respect to treatment or prevention of hepatitis C infection in mammals, one or more peptides that induce a CTL response to a hepatitis C antigen may be selected. The HCV CTL-inducing peptide will usually have at least four, sometimes six, often seven or more residues, or a majority of amino acids of that peptide that are identical or homologous when compared to the corresponding portion of the naturally occurring HCV sequence. For example, those peptides which are preferred for stimulating HCV CTL responses include sequences contained within copending U.S patent applications (Serial No. 08/159,339 and 08/073,205, previously incorporated herein by reference), in particular peptides 1073.05 (LLFNILGGWV) [Seq ID No. 46], 1090.18 (FLLLADARV) [Seq ID No. 49], 939.20 (LLALLSCLTV) [Seq ID No. 47], 1073.07 (YLLPRRGPRL) [Seq. ID No. 52], 1013.10 (DLMGYIPLV) [Seq ID No. 51], 1073.10 (GVAGALVAFK) [Seq ID No. 61]. Also suitable are other peptides identified by other methods, such as STNPKPQK [Seq ID No. 62] and GPRLGVRAT [Seq ID No. 63] (Koziel et al., J. Virol. 67:7522-7535, 1993), and YPWPLYGNEGGLWAGWLSP [Seq ID No. 64] (Kita et al., Abstract #631, 1993 Am. Assoc. For Study of Liver Diseases Meeting). Other HCV derived peptides for stimulating HCV CTL responses include the following:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HCV NS4	1807	LLPNILGGWV	10	46	3.5000
HCV CORE	178	LLALLSCLTV	10	47	0.6050
HCV NS4	1585	YLVAYQATV	9	48	0.2450
HCV NS1/ENV	725	FLLLADARV	9	49	0.2250
HCV NS4	1851	ILAGYGAGV	9	50	0.2150
HCV CORE	132	DLMGYIPLV	9	51	0.0835
HCV CORE	35	YLLPRRGPRL	10	52	0.0725
NS1/ENV2	686	ALSTGLIHL	9	53	0.0415
HCV CORE	178	LLALLSCLTY	10	54	0.0340
HCV NS5	2578	RLIVFPDLGV	10	55	0.0320
HCV NS5	2885	RLHGLSAFSL	10	56	0.0200
HCV NS4	1811	ILGGWVAAQL	10	57	0.0180
HCV ENV1	364	SMVGNWAKV	9	58	0.0155
HCV NS3	1131	YLVTRHADV	9	59	0.0109
HCV NS4	1666	VLAALAAAYCL	10	60	0.0106

20

With respect to treatment or prevention of HPV infections in mammals, one or more peptides that induce a CTL response to a HPV may be selected. The HPV CTL-inducing peptide will usually have at least four, sometimes six, often seven or more residues, or a majority of amino acids of that peptide that are identical or homologous when compared to the corresponding portion of the naturally occurring HCV sequence. For example, those peptides which are preferred for stimulating HPV CTL responses include sequences contained within copending U.S patent applications (Serial No. 08/159,339, 08/073,205 and EPO Patent Application 92201252.1, previously incorporated by reference), in particular the following peptides:

25

30

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HPV16 E7	82	LLMGTILGIV	9	65	0.0240
HPV16 E7	11	YMLDLQPET	9	66	0.1400
HPV16 E6	52	FAFRDLCIV	9	67	0.0570
HPV16 E7	86	TLGIVCPIC	9	68	0.0750
HPV16 E7	7	TLHEYMLDL	9	69	0.0070
HPV16 E7	85	GTLGIVCPI	9	70	0.0820
HPV16 E7	12	MLDLQPETT	9	71	0.0028
HPV16 E6	29	TIHDIILECV	10	72	0.0210

15 With respect to treatment or prevention of human immunodeficiency virus 1 and 2 in humans, one or more peptides that induce a CTL response to a HIV 1 or 2 antigen may be selected. The HIV CTL-inducing peptide will usually have at least four, sometimes six, often seven or more residues, or a majority of amino acids of that peptide that are identical or homologous when compared to the corresponding portion of the naturally occurring HIV sequence. For example, those peptides which are preferred for stimulating HIV CTL responses include the following peptides:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HIV	367	VLAEAMSQV	9	73	0.1100
HIV	1496	LLWKGEHAVV	10	74	0.0360
HIV	1496	LLWKGEHAV	9	75	0.0230
HIV	1004	ILKEPVHGV	9	76	0.0190
HIV	1129	IVGAETFYV	9	77	0.0099
HIV	1129	IIGAETFYV	9	78	0.0260
HIV	2182	LWVTVYYGV	9	79	0.0014
HIV	2182	LMVTVYYGV	9	80	0.4400

Several tumor associated antigens have also been correlated with CTL responses, including, but not limited to, renal cell carcinoma antigens, breast cancer antigens, 5 carinoembryonic antigen (CEA), melanoma (MAGE-1 and MAGE-3) antigens, prostate cancer specific antigen and others. For example, a HLA-A1-restricted CTL epitope for the tumor-associated antigen MAGE-3 has been identified using this approach and is the subject of a pending patent application (U.S. patent application Serial No. 08/186,266, previously 10 incorporated herein by reference.

Peptides which stimulate CTL responses to tumor antigens and which can be used in the methods and compositions of the present invention can be selected as described in, for example, U.S. Patent Applications Serial Nos. 08/159,339 and 15 08/073,205, previously incorporated by reference. For example, representative peptide which are preferred for inducing MAGE-3 and -1 CTL responses include the following:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
MAGE2	105	KMVELVHFL	9	81	0.5100
MAGE2	105	KMVELVHFL	10	82	0.2200
MAGE3	153	LVFGIELMEV	10	83	0.1100
MAGE1	278	KVLEYVIKV	9	84	0.0900
MAGE1	105	KVADLVGFLL	10	85	0.0560
MAGE3	105	KVAEFVHFL	9	86	0.0550
MAGE1	92	CILESLFRA	9	87	0.0460
MAGE1	264	FLWGPRALA	9	88	0.0420
MAGE1	200	VMIAMEGGHA	10	89	0.0360
MAGE1	38	LVLGTLVEV	9	90	0.0320
MAGE1	301	ALREEEEGV	9	91	0.0210
MAGE1	270	ALAETSYVKV	10	92	0.0150
MAGE1	282	YVIKVSARV	9	93	0.0140
MAGE1	269	RALAETSYV	9	94	0.0100

20

The present invention enhances the effectiveness of a CTL-inducing peptide by co-delivery with a sequence which contains at least one epitope that is capable of inducing a HTL response. By a HTL response is meant a CD4⁺ T lymphocyte response wherein CD4⁺ T lymphocytes are activated. The HTLs stimulated by the HTL-inducing peptide can be the T-helper 1 and/or T-helper 2 phenotype, for example. The activated T helper lymphocytes will secrete a variety of products, including, for example, interleukin-2, which may facilitate expression of the T cell receptor and promote recognition by activated CTLs.

25

HTL-inducing epitopes can be provided by peptides which correspond substantially to the antigen targeted by the CTL-inducing peptide, or more preferably is a peptide to a more widely recognized antigen, and preferably is not specific for a particular histocompatibility antigen restriction. Peptides which are recognized by most individuals regardless

30

35

of their MHC class II phenotype ("promiscuous") may be particularly advantageous. The HTL peptide will typically comprise from six to thirty amino acids and contain a HTL-inducing epitope. For example, illustrative peptides useful in the present invention are those which contain HTL inducing epitopes within a HTL peptide from tetanus toxoid 830-843 having the sequence Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu (QVIKANSKFIGITE) [Seq. ID No. 95], malaria circumsporozoite 382-398 Lys-Ile-Ala-Lys-Met-Lys-Ala-Ser-Ser-Val-Phe-Asn-Val-Val-Asn-Ser (KIAKMEKASSVFNVVNS) [Seq. ID No. 96]; malaria circumsporozoite 378-398 Asp-Ile-Glu-Lys-Lys-Ile-Ala-Lys-Met-Lys-Ala-Ser-Ser-Val-Phe-Asn-Val-Val-Asn-Ser (DIEKKIAKMEKASSVFNVVNS) [Seq. ID No. 97], and ovalbumin 323-336 Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-Glu [Seq. ID No. 98] and the influenza epitope 307-319 Pro-Lys-Tyr-Val-Lys-Gln-Asn-Thr-Leu-Lys-Leu-Ala-Thr [Seq. ID No. 99]. In addition suitable T helper peptides have been identified as described in pending U.S. Patent Application Serial No. 08/121,101, incorporated herein by reference.

Other examples of HTL-inducing peptides are those which are specific for the antigen (virus or other organism, tumor, etc.) being targeted by the CTL. For example, several HTL-inducing peptides specific for HBV have been described, such as HBC₁₋₂₀, having the sequence: Met-Asp-Ile-Asp-Pro-Tyr-Lys-Glu-Phe-Gly-Ala-Thr-Val-Glu-Leu-Leu-Ser-Phe-Leu-Pro [Seq. ID No. 100]; peptides from the region HBC₅₀₋₆₉, which has the sequence Pro-His-His-Tyr-Ala-Leu-Arg-Gln-Ala-Ile-Leu-Cys-Trp-Gly-Glu-Leu-Met-Tyr-Leu-Ala [Seq. ID No. 101], and from the region of HBC₁₀₀₋₁₃₉, including HBC₁₀₀₋₁₁₉ having the sequence Leu-Leu-Trp-Phe-His-Ile-Ser-Cys-Leu-Thr-Phe-Gly-Arg-Glu-Thr-Val-Ile-Glu-Tyr-Leu [Seq. ID No. 102] (where Ile₁₁₆ is Leu in the HBV adw subtype), HBC₁₁₇₋₁₃₁ having the sequence Glu-Tyr-Leu-Val-Ser-Phe-Gly-Val-Trp-Ile-Arg-Thr-Pro-Pro-Ala [Seq. ID No. 103], and peptide HBC₁₂₀₋₁₃₉ having the sequence Val-Ser-Phe-Gly-Val-Trp-Ile-Arg-Thr-Pro-Pro-Ala-Tyr-Arg-Pro-Pro-Ash-Ala-Pro-Ile [Seq. ID No. 104]. See, Ferrari et al., J. Clin. Invest. 88:214-222 (1991), and U.S. Pat. No. 4,882,145, and

U.S. Patent No. 5,143,726, each of which is incorporated herein by reference.

The CTL or HTL inducing peptides employed in the compositions and methods of the present invention need not be identical to specific peptides disclosed in aforementioned disclosures, and can be selected by a variety of techniques, for example, according to certain motifs as described above. Therefore, the peptides may be subject to various changes, such as insertions, deletions, and substitutions, either 5 conservative or non-conservative, where such changes might provide for certain advantages in their use. By conservative 10 substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, 15 Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. Usually, the portion of the sequence which is intended to substantially mimic a CTL or HTL stimulating 20 epitope will not differ by more than about 20% from the corresponding sequence of a native antigen, when known, except where additional amino acids may be added at either terminus 25 for the purpose of modifying the physical or chemical properties of the peptide for, e.g., ease of linking or coupling, and the like. In those situations where regions of the peptide sequences are found to be polymorphic among antigen subtypes, it may be desirable to vary one or more particular amino acids to more effectively mimic differing CTL 30 or HTL epitopes of different antigen strains.

In some instances it may be desirable to combine two or more peptides which contribute to stimulating specific CTL 35 responses in one or more patients or histocompatibility types. The peptides in the composition can be identical or different, and together they should provide equivalent or greater biological activity than the parent peptide(s). For example, using the methods described herein, two or more peptides may define different or overlapping CTL epitopes from a particular region, e.g., the peptide region 799.08 (HBenv309-328), peptide

region, 799.09 (HBenv₃₂₉₋₃₄₉), 799.10 (HBenv₃₄₉₋₃₆₈), or peptide region 802.03 (HBc₉₁₋₁₁₀), which peptides can be combined in a "cocktail" to provide enhanced immunogenicity of CTL responses, and peptides can be combined with peptides having different MHC restriction elements. This composition can be used to effectively broaden the immunological coverage provided by therapeutic, vaccine or diagnostic methods and compositions of the invention among a diverse population.

In some embodiments the CTL inducing peptides of the invention are linked to the HTL inducing peptides. CTL inducing peptides / T helper conjugates can be linked by a spacer molecule, or the CTL peptide may be linked to the HTL peptide without a spacer. When present, the spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions and may have linear or branched side chains. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. In certain preferred embodiments herein the neutral spacer is Ala. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. Preferred exemplary spacers are homo-oligomers of Ala. When present, the spacer will usually be at least one or two residues, more usually three to six residues. When the HTL-inducing peptide is conjugated to the CTL-inducing peptide, in the present or absence of a spacer, preferably with the HTL peptide is positioned at the amino end of the conjugate.

The peptides of the invention can be combined via linkage to form polymers (multimers), or can be formulated in a composition without linkage, as an admixture. Where the same peptide is linked to itself, thereby forming a homopolymer, a plurality of repeating epitopic units are presented. When the peptides differ, e.g., a cocktail representing different antigen strains or subtypes, different epitopes within a subtype, different histocompatibility

restriction specificities, or peptides which contain HTL epitopes, heteropolymers with repeating units are provided. In addition to covalent linkages, noncovalent linkages capable of forming intermolecular and intrastructural bonds are also contemplated.

Linkages for homo- or hetero-polymers or for coupling to carriers can be provided in a variety of ways. For example, cysteine residues can be added at both the amino- and carboxy-termini, where the peptides are covalently bonded via controlled oxidation of the cysteine residues. Also useful are a large number of heterobifunctional agents which generate a disulfide link at one functional group end and a peptide link at the other, including N-succidimidyl-3-(2-pyridyldithio) propionate (SPDP). This reagent creates a disulfide linkage between itself and a cysteine residue in one protein and an amide linkage through the amino on a lysine or other free amino group in the other. A variety of such disulfide/amide forming agents are known. See, for example, Immun. Rev. 62:185 (1982). Other bifunctional coupling agents form a thioether rather than a disulfide linkage. Many of these thioether forming agents are commercially available and include reactive esters of 6-maleimidocaproic acid, 2-bromoacetic acid, 2-iodoacetic acid, 4-(N-maleimido-methyl) cyclohexane-1-carboxylic acid and the like. The carboxyl groups can be activated by combining them with succinimide or 1-hydroxy-2-nitro-4-sulfonic acid, sodium salt. A particularly preferred coupling agent is succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC). Of course, it will be understood that linkage should not substantially interfere with either of the linked groups to function as described, e.g., to function as a CTL determinant or HTL determinant.

As a further aspect of the present invention the HTL-inducing peptide(s) and CTL-inducing peptide(s) can be delivered to the patient in the presence of a lipid. The lipid residue, such as palmitic acid or the like (as described further below, which is attached to alpha and epsilon amino

groups of a Lys residue ((PAM)₂Lys), is attached to the amino terminus of the HTL-inducing peptide. The lipid can be attached directly to the HTL peptide, or, more typically, indirectly via a linkage, such as a Ser-Ser, Gly, Gly-Gly, Ser linkage or the like.

As another example of lipid-HTL priming of CTL responses, *E. coli* lipoprotein, such as tripalmitoyl-S-glycercylcysteinyl-seryl-serine (P₃CSS), can be used to prime specific CTL when covalently attached to an appropriate HTL peptide. See, Deres et al., *Nature* 342:561-564 (1989), incorporated herein by reference. The HTL peptides can be coupled to P₃CSS, for example, and the lipopeptide administered in conjunction with the CTL inducing peptide to an mammal to specifically prime a CTL response to the antigen of interest.

Yet another example of lipid priming of CTL response is achieved by conjugating the CTL/T helper-peptide-conjugate with uncharged fatty acid residues of different chain lengths and degrees of unsaturation, ranging from acetic to stearic acid as well as to negatively charged succinyl residues via the appropriate carboxylic acid anhydrides.

The lipid may be linked to other peptides which present HTL epitopes which are then combined with the lipid. When the HTL and CTL are linked in a conjugate, the arrangement of the components of the conjugate comprising the CTL inducing peptide/T helper peptide/lipid can be varied. In one case, the lipid moiety can be linked to the amino terminal end of the CTL inducing peptide, which in turn is linked at its carboxy terminal to the T helper peptide. In another case, the lipid is linked at the amino terminal end of the T helper peptide, which is linked at its carboxy terminal to the CTL inducing peptide. In each case, a spacer molecule can be selectively inserted between the lipid moiety and the CTL or T helper peptide, as well as between the T helper and the CTL inducing peptides. In the case of the spacer between the lipid and the T helper or CTL inducing peptide, a preferred example comprises Lys-Ser-Ser, although other spacers are

described herein. An example of a spacer between the T helper and CTL inducing peptides will be Ala-Ala-Ala, as also described in further detail herein.

As further described herein, the lipidated HTL peptide and CTL peptide can then be emulsified in an adjuvant, e.g., incomplete Freund's adjuvant, alum or montanide.

In an exemplary embodiment described below, a T helper peptide from substantially within TT830-843 was lipidated at its N-terminus (with (PAM)₂) via a linker (KSS) and then linked at its C-terminus (via a linker AAA) with a HBV CTL inducing peptide, HBc18-27. Thus, the structure of the peptide was (PAM)₂KSS-T helper-AAA-CTL and had the sequence of (PAM)₂KSS-ISQAVHAAHAEINE-AAA-TYQRTRALV [Seq ID No. 105]. This conjugate, when administered to transgenic animals expressing the HLA2.1 antigen, was shown to induce specific CTL priming of animals. It was also established that the CTL induced by the peptide recognized endogenously synthesized HBcore antigens. When the same lipid-THL-CTL peptide conjugate was administered to humans an induction of specific CTL response was observed, where the response dose dependent both in proportion of subjects exhibiting a positive response as well as in the magnitude of the response obtained.

The peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co. (1984); Tam et al., J. Am. Chem. Soc. 105:6442 (1983); Merrifield, Science 232:341-347 (1986); and Barany and Merrifield, The Peptides, Gross and Meienhofer, eds., Academic Press, New York, pp. 1-284 (1979), each of which is incorporated herein by reference.

Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes a CTL peptide and/or T helper peptide of interest is inserted into

an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1982), and Ausubel et al., (ed.) Current Protocols in Molecular Biology, John Wiley and Sons, Inc., New York (1987), and U.S. Pat. Nos. 4,237,224, 4,273,875, 4,431,739, 4,363,877 and 4,428,941, for example, which disclosures are incorporated herein by reference. Thus, fusion proteins which comprise one or more peptide sequences can be used to present the CTL and HTL determinants. For example, a recombinant HBenv surface antigen protein is prepared in which the HBenv amino acid sequence is altered so as to more effectively present epitopes of peptide regions described herein to stimulate a CTL response. By this means a polypeptide is used which incorporates several CTL and HTL epitopes.

As the coding sequence for peptides of the length contemplated herein can be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981), modification can be made simply by substituting the appropriate base(s) for those encoding the native peptide sequence. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable

bacterial hosts. Of course, yeast or mammalian cell hosts may also be used, employing suitable vectors and control sequences.

The peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent viral, bacterial, and parasitic infections. As the peptides are used to stimulate cytotoxic T-lymphocyte responses to HBV infected cells, the compositions can be used to treat or prevent acute and/or chronic HBV infection.

For pharmaceutical compositions, the peptides, i.e., the compositions of lipidated HTL/CTL peptides of the invention as described above will be administered to a mammal already suffering from or susceptible to the disease being treated. Those in the incubation phase or the acute phase of disease such as a viral infection, e.g., HBV, can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate. In therapeutic applications, compositions are administered to a patient in an amount sufficient to elicit an effective CTL response to the disease and to cure or at least partially arrest its symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0 μ g to about 50 mg, preferably 1 μ g to 500 μ g, most preferably 1 μ g to 250 μ g followed by boosting dosages of from about 1.0 μ g to 50 mg, preferably 1 μ g to 500 μ g, and more preferably 1 μ g to about 250 μ g of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood. It must be kept in mind that the peptides and compositions of the

present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of cytotoxic T-lymphocyte stimulatory peptides of the invention sufficient to effectively treat the patient.

For therapeutic use, administration should begin at the first sign of disease (e.g., HBV infection), to be followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In cases of established or chronic disease, such as chronic HBV infection, loading doses followed by boosting doses may be required. The elicitation of an effective CTL response during early treatment of an acute disease stage will minimize the possibility of subsequent development of chronic disease such as hepatitis, HBV carrier stage, and ensuing hepatocellular carcinoma.

Treatment of an infected mammal with the compositions of the invention may hasten resolution of the disease in acutely afflicted mammals. For those mammals susceptible (or predisposed) to developing chronic disease the compositions of the present invention are particularly useful in methods for preventing the evolution from acute to chronic disease. Where the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.

The peptide compositions can also be used for the treatment of chronic or established disease such as viral hepatitis and to stimulate the immune system to eliminate

virus-infected cells. Those with chronic hepatitis can be identified as testing positive for virus from about 3-6 months after infection. As individuals may develop chronic HBV infection because of an inadequate (or absent) CTL response during the acute phase of their infection, it is important to provide an amount of immuno-potentiating peptide compositions of the invention in a formulation and mode of administration sufficient to effectively stimulate a CTL response. Thus, for treatment of chronic hepatitis, a representative dose is in the range of about 1.0 μ g to about 50 mg, preferably 1 μ g to 500 μ g, most preferably 1 μ g to 250 μ g followed by boosting dosages of from about 1.0 μ g to 50 mg, preferably 1 μ g to 500 μ g, and more preferably 1 μ g to about 250 μ g per dose.

Administration should continue until at least clinical symptoms or laboratory indicators indicate that the HBV infection has been eliminated or substantially abated and for a period thereafter. Immunizing doses followed by boosting doses at established intervals, e.g., from one to four weeks, may be required, possibly for a prolonged period of time, as necessary to resolve the infection. For the treatment of chronic and carrier HBV infection it may also be desirable to combine the CTL and HTL peptides with other peptides or proteins that induce immune response to other HBV antigens, such as HBsAg.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the HTL and CTL stimulatory peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous

5 solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, methanol, and dissolving agents such as DMSO, etc.

10 The concentration of HTL and CTL stimulatory peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 1%, usually at or at least about 10% to as much as 20 to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

15 Thus, a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 50 mg of peptide. Actual methods for preparing parenterally administrable compounds will be known or apparent to those skilled in the art and are described in more detail in for example, Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference.

20 The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or targeted selectively to infected cells, as well as increase the half-life of the peptide composition. Liposomes include emulsions, 25 foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule 30 which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 35 cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic

compositions. Thus, liposomes filled with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, incorporated herein by reference. For targeting to the immune cells, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptide compositions of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the HTL and CTL stimulatory peptide compositions are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight,

preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

In another aspect the present invention is directed to vaccines which contain as an active ingredient an immunogenically effective amount of a composition of HTL and CTL stimulating peptides as described herein. The peptide(s) may be introduced into a mammalian host, including humans, linked to its own carrier or as a homopolymer or heteropolymer of active peptide units. Such a polymer has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies and/or cytotoxic T cells that react with different antigenic determinants of the virus. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(D-lysine:D-glutamic acid), influenza protein and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, alum, or montanide are materials well known in the art. Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the disease associated

antigen, and the host becomes at least partially immune to the disease, e.g., HBV infection, or resistant to developing chronic disease.

Vaccine compositions containing the peptides of the invention are administered to a patient susceptible to or otherwise at risk of disease, e.g., viral infection, to enhance the patient's own immune response capabilities. Such an amount is defined to be a "immunogenically effective dose." In this use, the precise amounts depend on the patient's state of health, age, the mode of administration, the nature of the formulation, etc.,. The peptides are administered to individuals of an appropriate HLA type, e.g., for vaccine compositions of peptide HBC 18-27, these will be administered to HLA-A2 individuals.

In some instances it may be desirable to combine the peptide vaccines of the invention with vaccines which induce neutralizing antibody responses to the disease, e.g., HBV, particularly to HBV envelope antigens, such as recombinant HBV env-encoded antigens or vaccines prepared from purified plasma preparations obtained from HBV-infected individuals. A variety of HBV vaccine preparations have been described, and are based primarily on HBsAg and polypeptide fragments thereof. For examples of vaccines which can be formulated with the peptides of the present invention, see generally, European Patent publications EP 154,902 and EP 291,586, and U.S. Patent Nos. 4,565,697, 4,624,918, 4,599,230, 4,599,231, 4,803,164, 4,882,145, 4,977,092, 5,017,558 and 5,019,386, each of which is incorporated herein by reference. The vaccines can be combined and administered concurrently, or as separate preparations.

The peptides may also find use as diagnostic reagents. For example, a peptide of the invention may be used to determine the susceptibility of a particular individual to a treatment regimen which employs the peptide or related peptides, and thus may be helpful in modifying an existing treatment protocol or in determining a prognosis for an affected individual. In addition, the peptides may also be

used to predict which individuals will be at substantial risk for developing chronic HBV infection.

5 The following examples are offered by way of illustration, not by way of limitation.

EXAMPLE 1
IDENTIFICATION OF CTL-SPECIFIC HBV EPITOPES

10 A line of transgenic mice which express a mouse-human chimeric class I molecule was used to define HBV core and surface antigen sequences that represent CTL-specific epitopes.

15 The transgenic mouse line 66 obtained from Scripps Clinic and Research Foundation expresses a chimeric class I molecule composed of the $\alpha 1$ and $\alpha 2$ domains of human HLA-A2.1 antigen and the 3 transmembrane and cytoplasmic domains of H-2K^b. The transgenic mice were prepared as generally described in Vitiello et al., J. Exp. Med. 173:1007-1015 (1991), which is incorporated herein by reference. When these mice are 20 primed in vivo with the influenza virus, they generate a CTL response that is specific for virtually the same epitopes as those recognized by human influenza-specific CTL. Thus, these transgenic animals can be used to determine HBV epitopes 25 recognized by human T cells.

25 To define which sequence regions within HBV surface and core proteins represented CTL epitopes, synthetic peptides derived from the two proteins were prepared and tested for their ability to bind to human HLA-A2.1. Binding was 30 determined by the relative capacity of different peptide concentrations to inhibit recognition of A2.1 target cells in the presence of the influenza matrix peptide 57-68 by the CTL line 219, as determined by the inhibition of release of serine esterase from the cells. The 219 line was derived from A2.1 35 transgenic mice and is specific for the matrix peptide 57-68 in the context of HLA-A2.1.

Briefly, peptides to be assayed for CTL epitopes were dissolved in DMSO at a concentration of 20 mg/ml. Just before the assay, peptides were diluted in RPMI 1640 buffered with 25 μ M Hepes and containing .05% BSA (assay media). Fifty microliters of a 200 μ g/ml, 66 μ g/ml, or 22 μ g/ml of peptide solution were added to wells of 96 round-bottomed plates containing 4×10^5 Jurkat A2.1/K^b cells in a volume of 50 μ l of assay media. Plates were incubated for 30 min. at 37°C. Fifty μ l of 2.5 μ g/ml solution of the index peptide (matrix peptide 57-68 from PR8 influenza virus) were then added to the cells, followed by 50 μ l containing 5×10^4 line 219 CTL, where the concentration of index peptide used was chosen as that which induced 75% serine esterase release from CTL 219, as determined by titration of the peptide. After 4 hours incubation at 37°C, plates were centrifuged for 5 min. at 1000 RPM, and 20 μ l supernatant transferred to flat-bottomed 96-well plates. Esterase activity in the supernatant was measured by adding 180 μ l of a reaction mixture consisting of 0.2M TrisHCl pH 8.1, 2.0×10^{-4} M-benzylloxycarbonyl-L-Lysine thiobenzyl ester (BLT) and 2.2×10^{-4} M dithiobis (nitrobenzoic acid). Plates were incubated for 1 hour at 37°C and absorbance read at 412 nm. Percent inhibition was calculated by the following formula:

$$25 \quad \text{inhibition} = 100 - \frac{A_{412} \text{ (test + index) peptide} - A_{412} \text{ Test peptide alone}}{A_{412} \text{ index peptide} - A_{412} \text{ no peptide}} \times 100$$

Those peptides which bound to A2.1 and caused more than 24% inhibition of serine esterase release by the cells were assayed *in vitro* for the ability to restimulate a CTL response from splenocytes derived from HBV primed A2.1 transgenic mice. (Sette, A. et al., J. Immunol. 147:3893 (1991)). HBV priming was performed by injecting A2.1 spleen cells "loaded" with HBV virus as described by Carbone and Bevan, J. Exp. Med. 171:377-387 (1990).

Briefly, red blood cell depleted splenocytes were suspended in .4 ml of a solution composed of 200 μ l of HBV

purified virus and 200 μ l of a 2 x hypertonic solution (0.5 M sucrose, 10% w/v polyethylene glycol 1000, 10 mM Hepes, pH 7.2, in RPMI 1640 medium), for 10 min. at 37°C. The cell suspension was then rapidly diluted in prewarmed hypotonic media (60% HBSS and 40% water), incubated for 2 min. at 37°C, pelleted, washed twice in HBSS and irradiated (1,000 rad.). Mice were then injected with 5.0×10^6 loaded cells in a volume of 200 μ l. Mice were boosted with HBV-loaded spleen cells 10 days later.

After about 2 weeks, spleen cells from primed mice (5×10^6 cells/well in 24 well plates) were cultured with 4 different mixtures of syngeneic irradiated (3000 rads) LPS blasts (2×10^6 cells/well) that had been independently coated with 13 different peptides. Coating was achieved by incubating aliquots of 25×10^6 LPS blasts in tubes each with 100 μ g of one of the 13 HBV synthetic peptides in one mL for 1-2 hrs at 37°C; the contents of the different tubes were then pooled to give 4 mixtures.

	<u>Mixture No.</u>	<u>Peptide No.</u>	<u>Peptide Location</u>
20	1	800.04	HBenv47-63
		802.01	HBc11-27
		802.06	HBc162-176
25	2	801.02	HBenv141-157
		799.02	HBenv194-213
		802.03	HBc91-110
30	3	799.09	HBenv329-348
		799.10	HBenv349-368
		802.04	HBc111-125
		799.04	HBenv234-253
35	4	799.05	HBenv246-265
		799.08	HBenv309-328
		800.05	HBenv63-77

The mixture of cells was washed once, diluted at the required concentration and plated. The medium used for the cultures was RPMI 1640 supplemented with 10% FCS, 50 μ g/ml gentamicin,

2mM glutamine and 5×10^{-5} M 2-mercaptoethanol (R10). After nine days, effector cells were assayed for cytotoxicity against Jurkat A₂/K^b target cells in the presence of different peptide mixtures corresponding to those used in the cultures. The results obtained are shown in Fig. 1 panels, A through D. The effector cells (0.2×10^6 cells/well) obtained from these cultures were restimulated with irradiated (20,000 rads), peptide-coated Jurkat A₂/K^b cells (0.2×10^6 cells/well) in the presence of 3×10^6 feeder cells/well (C57BL/6 irradiated spleen cells) in R10 supplemented with 5% rat ConA supernatant. After 6 days, these effector cells were assayed for cytotoxicity against ⁵¹Cr labeled Jurkat A₂/K^b target cells in the presence of the 13 individual peptides. Peptides that induced CTL lysis of Jurkat A₂/K^b target cells above background (Fig. 1, panels E through H) i.e., HBenv 47-63, HBc 11-27 (panel E) HBenv 141-157, HBenv 194-213, HBc 91-110 (panel F), HBenv 329-348 and 349-368 (panel G) and HBenv 309-328 (panel H) were independently used to restimulate the effector cells generated with the peptide mixtures. After 6d in culture, the effector cells were tested for cytotoxicity against ⁵¹Cr Jurkat A₂/K^b cells in the presence of the peptide used for the restimulation (Fig. 1). The set of experiments, outlined in this example allow us to determine that HBV peptides HBc 11-27 (Fig. 1 panels A,E; Fig. 2 panel J) HBc 91-110 (Fig. 1 panels B,F; Fig. 2 panel M), HBenv 329-348 (Fig. 1 panels C,G; Fig. 2 panel N) HBenv 349-368 (Fig. 1 panels C,G; Fig. 2 panel O) and HBenv 309-328 (Fig. 1 panels D,H; Fig. 2 panel P) clearly represent CTL epitopes.

30

EXAMPLE 1A**INDUCTION OF OVALBUMIN-SPECIFIC CTL
RESPONSE IN MICE**

35

B6 mice were injected with 10, 50, or 200 μ g of ovalbumin in HBSS intravenously, intraperitoneally and subcutaneously with 10, 50, 200 μ g ovalbumin subcutaneously in IFA. Ten days later, splenocytes from primed animals were stimulated in vitro with irradiated EG7 cells (EL-4 cells

transfected with OVA). Six days later, the effector cells were tested for cytolytic activity against ^{51}Cr labelled EL-4 and EG7 cells. No CTL activity was induced by injection of ovalbumin in HBSS either intravenously or interperitoneally. Some CTL induction was seen at the 200 μg dose for subcutaneous injection of ovalbumin in HBSS. Strong CTL *in vivo* induction was seen when ovalbumin was administered with IFA, optimal induction occurred with the 10 μg dose given subcutaneously.

10

EXAMPLE 2

INDUCTION OF A2.1-RESTRICTED CTL
BY SUBCUTANEOUS PRIMING WITH PURIFIED HBV
IN INCOMPLETE FREUND'S ADJUVANT (IFA)

15

Injection of ovalbumin (OVA) in IFA subcutaneously induces an ovalbumin-specific CTL response in mice, while injection of OVA either i.v. or i.p. generally does not lead to the generation of CTL. This technique was used to induce HBV-specific CTL in A2.1 transgenic mice.

20

Priming and In Vitro Restimulation: A2.1/K^b
transgenic mice were injected with 100 microliters of an emulsion of purified HBV virus in incomplete Freund's adjuvant (IFA). This emulsion was prepared by mixing purified HBV (1 mg protein/ml) diluted 1:5 in HBSS with an equal volume of IFA. Seven days after priming, splenocytes (5×10^6 cells/well in a 24 well plate) obtained from these animals were restimulated with syngeneic irradiated LPS blasts (2×10^6 /well) coated with each of the following peptides:

30	799.09	HBenv 329-348	802.03	HBc 91-110
	875.20	HBenv 335-343	883.02	HBc 92-101
	875.21	HBenv 338-347	883.03	HBc 93-102
	799.10	HBenv 349-368	875.15	HBc 18-27
	884.01	HBenv 348-357	875.18	HBc 107-115
35	884.02	HBenv 349-358	875.19	HBc 139-148

These peptides were chosen because: 1) They had been defined as containing CTL epitopes in Example I (peptides 799.10, 799.09, 802.03); 2) they represent truncations of peptides defined in Example I that are recognized by the CTL raised against the larger epitopes (i.e., peptides 875.15, 884.02, 883.02, 883.03); or 3) they contain the A2.1 binding motif as described by Falk et al. (Nature 351:290-296 (1991)), i.e., leucine or methionine in position 2, and either leucine or valine in position 9 or valine in position 10, (i.e., peptides 884.01, 875.20, 875.21, 875.18 and 875.19). Coating was achieved by incubating 50 µg of each individual peptide with 12×10^6 LPS blasts in a volume of 0.4 ml of RPMI medium supplemented with 10% FCS for 1h at 37°C. The cells were washed once. After 6 days, effector cells were assayed for cytotoxicity against ^{51}Cr labelled Jurkat A2/K^b cells in the presence of the appropriate peptides. The results are shown in Fig. 3.

These effector cells ($.2 \times 10^6$ cells/well) were restimulated at weekly intervals. For the first restimulation, peptide-coated LPS blasts were used, followed by peptide-coated Jurkat A2.1/K^b cells. Six days after restimulation, effector cells were assayed for cytotoxicity against ^{51}Cr labelled Jurkat A2/K^b target cells in the presence of the appropriate peptides. The results obtained are shown in Fig. 4.

Peptides clearly able to induce in vitro CTL from splenocytes of HBV-primed mice are Fig. 3 and 4, panel A: HBc 18-27; Fig. 3 and 4, panel B: HBenv 349-368; Fig. 3 and 4, panel D: HBenv 349-358; Fig. 3 and 4, panel F: HBenv 329-348; Fig. 3 and 4, panel I: HBc 91-110; Fig. 3 and 4, panel J: HBc 92-102; and Fig. 3 and 4, panel K: HBc 93-102. Truncation peptides recognized by CTL raised against the larger peptide and as such should contain at least part of a CTL epitope are: Fig. 3F, 4F: HBenv 335-343 and HBenv 338-347.

EXAMPLE 2A

OTHER HBV CTL EPITOPES

The following peptides were identified following procedures disclosed in pending U.S. Patent Applications Serial No. 08/159,339 and 08/073,205, incorporated herein by reference.

<u>CTL Epitopes Position</u>		<u>Sequence</u>	<u>Seq. ID No.</u>
HBV POL	561	FLLSLGIHL-COOH	35
HBV POL	61	GLYSSTVPV-COOH	106
HBV POL	411	NLSWLSLDV-COOH	107
HBV POL	491	HLYSHPIIL-COOH	108

EXAMPLE 3

SYNTHESIS OF PEPTIDES

Peptides were synthesized on an Applied Biosystems (Foster City, CA) 430A peptides synthesizer using Fmoc protected amino acids and 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) esters for amino acid activation. Each amino acid was routinely triple coupled. Fmoc protected amino acids and Hydroxybenzotriazole were purchased from Burdick and Jackson. HBTU was purchased from Richelieu Biotechnologies (St-Hyacinthe, Canada). Piperidine and trifluoroacetic acid, acetic anhydride, and ethanedithiol were purchased from Sigma Chemical Corporation.

a. Peptide Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val-OH [Seq. ID No. 4]

L-Valine coupled to Sasrin® resin (Bachem Biosciences) was loaded into the peptide synthesis reaction vessel and washed one time with N-methylpyrrolidone (NMP). The following operations were then sequentially performed:

1. The Fmoc protecting group was removed by treatment of the resin bound amino acid with 25% piperidine in NMP.
2. The resin was washed 5 times with NMP.
3. A mixture containing Fmoc-serine, diisopropylethylamine, HBTU and NMP was added to the reaction vessel and allowed to react for 30 minutes, under vortex agitation.
4. The solvent was drained, and the resin was washed three times with NMP.
5. Steps (3) and (4) were repeated two more times.
6. The resin was washed four more times with NMP.

10 Steps 1-6 were repeated for each amino acid of the peptide. Following the final coupling cycle, the resin-bound peptide was deprotected by reaction with 25% piperidine in NMP, washed 7 times with NMP, and washed 2 times with dichloromethane.

15 The resin was dried in vacuo for 24 hours. The peptide was cleaved from the Sasrin® resin by treatment with trifluoroacetic acid containing 2.5% ethanedithiol and 5% water. The polystyrene resin was separated from the trifluoroacetic acid solution by filtration. Trifluoroacetic acid was removed by evaporation in vacuo. The crude peptide was triturated with diethylether and dissolved in water. The water was removed by lyophilization. The peptide was then purified by reverse phase HPLC on a C₈ column (VYDAC) using a gradient of acetonitrile, water, each containing 0.1% TFA as modifier.

20 b. Peptide (Pal)₂-Lys-Ser-Ser-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val-OH [Seq. ID No. 109]

30 The resin bound peptide described in section a was extended by the addition of two serine residues according to the above described procedure. The following operations were then performed:

1. The Fmoc protecting group was removed by treatment of the resin bound amino acid with 25% piperidine in NMP.
2. The resin was washed 5 times with NMP.
3. Bis-Fmoc-Lysine was converted to the corresponding symmetrical anhydride by treatment with

diisopropylcarbodiimide in NMP. The resin bound peptide was allowed to react with the resulting anhydride.

4. The resin was washed 5 times with NMP.

5. The Fmoc protecting group was removed by treatment of the resin bound amino acid with 25% piperidine in NMP.

6. Palmitic acid was reacted with hydroxybenzotriazole and diisopropylcarbodiimide in NMP. The resin bound peptide was allowed to react with the resulting solution.

7. The resin was washed 5 times with NMP.

10 Finally, the peptide was cleaved from the resin as described above.

c. Peptide Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val-OH [Seq. ID No. 110]. The resin bound peptide described in section a was chain extended by the addition of Glu, Thr, Ile, Gly, Ile, Phe, Lys, Ser, Asn, Ala, Lys, Ile, Tyr, and Gln residues, according to the procedure described in Section a. Cleavage and purification were performed as described above.

d. Peptide Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val-OH [Seq. ID No. 111]. The resin bound peptide described in section a was chain extended by the sequential addition of Ala, Ala, Ala, Glu, Thr, Ile, Gly, Ile, Phe, Lys, Ser, Asn, Ala, Lys, Ile, Tyr, and Gln residues, according to the procedure described in section a. Cleavage and purification were performed as described above.

e. Peptide Ac-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val-OH [Seq. ID No. 112]. The resin bound peptide described in Section d was acetylated by reaction with acetic anhydride in NMP. Cleavage and purification were performed as described above.

EXAMPLE 4
INDUCTION OF CTL BY COMBINING
CTL AND T-HELPER EPITOPES

5. This example describes experiments which define the relative *in vivo* HBV-specific CTL priming efficiency of peptides expressing HBV CTL epitopes alone, CTL epitopes mixed with peptides containing T helper epitopes or CTL epitopes physically linked to T helper epitopes.

10. Transgenic mice (HLA-A2.1/K^b) were primed subcutaneously (base of tail) with 100 µg of peptide 875.23 (Ia^b-restricted helper epitope HBc 128-140 TPPAYRPPNAPIL (Seq ID No. 113)) in complete Freund's adjuvant (CFA). Nine days later each of the following peptides were injected 15. subcutaneously into two unprimed and two helper-primed mice, 100 µg/mouse in incomplete Freund's adjuvant (IFA).

	<u>Peptide</u>	<u>T Helper (HBc 128-140)</u>	<u>CTL (HBc 18-27)</u>	<u>Seq ID No.</u>
20	1. 875.23	TPPAYRPPNAPIL		113
	2. 875.15		FLPSDFFPSV	4
	3. 875.23+875.15	TPPAYRPPNAPIL	+	113 & 4
	4. 902.01 =	TPPAYRPPNAPILFLPSDFFPSV-NH ₂		114
	5. 902.02	TPPAYRPPNAPILAAFLPSDFFPSV-NH ₂		115
25	6. No peptide			

30. Three weeks after priming with the CTL epitope, splenocytes were *in vitro* restimulated with LPS blasts coated with HBc 18-27 (coating was achieved by incubating 30 x 10⁶ LPS blasts with 100 µg of HBc18-27 in one ml of medium; after 1-2 hr at 37°C, the cells were washed). After 6 days, effector cells were assayed for lytic activity against ⁵¹Cr labelled Jurkat A₂/K^b target cells in the presence or absence of HBc18-27.

35. The results showed that in 50% of the animals studied in which the T helper and CTL epitope peptides were simply mixed (i.e., not linked) and administered in an immunizing dose, induction of some detectible antigen-specific CTL

activity above the level of background killing was seen. An example of the response detected is shown in Fig. 7. Surprisingly, when animals were primed with the T helper epitope linked to the CTL epitope, 100% showed evidence of specific CTL priming (Fig. 8), the magnitude of which was greater than that detected when the epitopes were administered non-linked (Fig. 7). Quite unexpectedly, as shown in Fig. 9, it was found that linking the T helper and CTL epitopes via an alanine-alanine-alanine spacer (i.e., T helper-AAA-CTL) resulted in the induction of specific CTL activity greater than that detected by linking the T helper and CTL determinants alone. Priming with the T helper peptide or CTL peptide alone did not induce HBc-specific CTL (Figs. 5 and 6). Also, prior immunization of animals to induce T helper-specific immunity did not appear to be essential for priming for CTL using either the T helper and CTL mixture or the T helper-CTL conjugate, since immunization was detected when naive animals were primed with the appropriate conjugate (Figs. 10A and B).

20

EXAMPLE 4A
**RECOGNITION OF GENERATION OF ENDOGENOUS
PROCESSED ANTIGENS AFTER PRIMING**

This example discloses that CTL inducted by *in vivo* priming with peptide (as disclosed in Example 4) recognize endogenously synthesized antigens.

A fraction of the effector cells from the procedure disclosed in Example 4 whose CTL function is represented in Figs. 7, 8 and 9, were restimulated *in vitro* using HBcAg 18-27-coated JA2.1/K^b stimulator cells. Six days later, effector cells were assayed for cytotoxicity and the cell lines that contained HBcAg 18-27-specific cytotoxic activity were further restimulated. Six days later, these cell lines were tested for cytotoxic activity on ⁵¹Cr labeled Jy S1 target cells in the absence or presence of HBcAg 18-27 and on ⁵¹Cr labeled Jy core target cells, as demonstrated in the following table.

CTL lines obtained from animals primed with HBcAg 18-27 peptide derived
recognize endogenously synthesized HBc antigen.

5

	Animal No.	In vivo Primed			JV S ₁	NoAg	Jy Core	
			Day 0	Day 9			875.15	
10	H21	—	902.01	0.1:1	1	43	3	
				0.5:1	3	66	2	
				2:1	6	73	9	
				8:1	11	74	1.5	
15	H5-2	—	902.02	0.3:1	2	55	21	
				1:1	1	78	35	
				4.5:1	5	77	44	
				18:1	12	82	54	
20	H6-3	—	875.15 +875.23	0.4:1	4	67	9	
				1.5:1	6	78	17	
				6:1	11	75	23	
				24:1	18	79	29	
25	H4-6	875.23	902.01	0.15:1	2	29	9	
				0.6:1	5	51	21	
				2.5:1	12	63	32	
				10:1	21	62	42	
30	H4-2	875.23	902.02	0.6:1	1	74	37	
				2.5:1	3	80	55	
				10:1	6	80	59	
				40:1	14	77	63	

35

All CTL lines were specific for HBcAg 18-27 and recognized Jy core albeit to a different extent. The much higher level of lysis obtained in the presence of exogenously added peptide as compared to endogenously synthesized, is explained by the relatively greater concentration of peptide that can be added exogenously. Because CTL lines derived from both animals primed with 902.02 had the highest affinity for endogenous antigen (producing a 35% and 37% specific lysis of Jy core at the E:T of 1:1 and 0.6:1, respectively), it is demonstrated that this construct, i.e., T helper epitope AAA HBcAg 18-27 possesses immunogenic characteristics suitable for induction of cells that recognize HBV infected cells.

50

EXAMPLE 5
INDUCTION OF A2.1-RESTRICTED CTL-SPECIFIC
FOR HBenv₃₆₀₋₃₆₈

5 A2/K^b transgenic mice were injected with 100 microliters of an emulsion of 100 µg HBenv₃₆₀₋₃₆₈ and 100 µg HBC₁₂₈₋₁₄₀ helper epitope in incomplete Freund's adjuvant (IFA). (This emulsion was prepared by mixing 500 µg of both peptides in PBS with an equal volume of IFA.) Twenty-one days
10 after priming, splenocytes (5x10⁶ cells/well in a 24-well plate) obtained from these animals were restimulated with syngeneic LPS blasts (2x10⁶/well) coated with the peptide HBenv₃₆₀₋₃₆₈. These effector cells (0.2x10⁶/well) were restimulated at weekly intervals. For the first and second
15 restimulations, HBenv₃₆₀₋₃₆₈ coated LPS blasts were used, followed by HBenv₃₆₀₋₃₆₈ coated Jurkat A2.1/K^b cells. Six days after restimulation, effector cells were assayed for cytotoxicity against ⁵¹Cr labelled Jurkat A2/K^b target cells in the presence and absence of HBenv₃₆₀₋₃₆₈ (see Fig. 11).
20 Therefore, HBenv₃₆₀₋₃₆₈ is a CTL specific epitope.

EXAMPLE 6
TESTING OF LINKED TETANUS TOXOID T HELPER AND
HBC CYTOTOXIC T CELL EPITOPES FOR *in vivo* PRIMING

25 Transgenic mice (HLA-A2-1/kb) were primed subcutaneously (base of the tail) with 200 mg (0.07 mM) of peptide 934.02.

	<u>Peptide</u>	<u>Tetanus Toxoid 830-843</u> <u>T Helper Epitope</u>	<u>Linker</u>	<u>HBV core 18-27</u> <u>CTL Epitope</u>	<u>Seq</u> <u>ID No.</u>
30	934.02	AC-QYIKANSKFIGITE	AAA	FLPSDFFFFPSV	112

35 Three weeks after priming, splenocytes were restimulated *in vitro* with LPS blasts coated with HBC 18-27 (as described in example I). After 7 days cells were restimulated with jurkat A2/Kb cells coated with HBC 18-27 (as described in Example I) - After 6 days these effector cells

were assayed for cytotoxicity against ^{51}Cr labeled jurkat A2/Kb target cells in the presence or absence of HBC 18-27, JY target cells in the presence or absence of HBC 18-27 and JY cells transfected with HBV core. The results, shown in Fig. 5 12, indicate that peptide 934.02 effectively induces CTL specific for HBC 18-27. Moreover, these CTL recognize and kill endogenously presented antigen (JY core).

EXAMPLE 7

10 COMPARISON OF CTL IMMUNITY INDUCED
BY PEPTIDE IMMUNIZATION

15 Various modifications and formulations of an antigenic CTL peptide were tested in an effort to enhance its immunogenicity. BALB/c mice were primed subcutaneously in the base of the tail with one of the following peptides or peptide mixtures:

	<u>Peptide or Peptides</u>	<u>Dose $\mu\text{M}/\text{mouse}$</u>	<u>Formulation</u>
20	932.01 CTL (Flu NP 147-155) TYQRTRALV [Seq ID No. 116]	0.1, 0.01	Saline, Alum, IFA
25	932.07 (PAM) ₂ KSS-CTL (PAM) ₂ KSSTYQRTRALV [Seq ID No. 117]	0.1, 0.01	Saline, Alum, IFA
30	932.01 CTL + T helper (OVA 323-336) +577.01 TYQRTRALV-ISQAVHAAHAEINE [Seq ID No. 118]	0.1, 0.01 ea.	Saline, Alum, IFA
35	932.07 (PAM) ₂ KSS-CTL + T helper +577.01 (PAM) ₂ KSSTYQRTRALV-ISQAVHAAHAEINE [Seq ID No. 119]	0.1, 0.01	Saline, Alum, IFA
40	932.02 T helper-CTL ISQAVHAAHAEINE-TYQRTRALV [Seq ID No. 120]	0.1, 0.01	Saline, Alum, IFA
45	932.04 (PAM) ₂ KSS-T helper-CTL (PAM) ₂ KSSISQAVHAAHAEINE-TYQRTRALV [Seq ID No. 121]	0.1, 0.01	Saline, Alum, IFA
	932.03 T helper-AAA-CTL ISQAVHAAHAEINE-AAA-TYQRTRALV [Seq ID No. 122]	0.1, 0.01	Saline, Alum, IFA
	932.05 (PAM) ₂ KSS-T helper-AAA-CTL (PAM) ₂ KSS-ISQAVHAAHAEINE-AAA-TYQRTRALV [Seq ID No. 105]	0.1, 0.01	Saline, Alum, IFA

Three weeks after immunization splenocytes were removed and stimulated *in vitro* with the flu 147-155 peptide. CTL activity was assayed one week later using ^{51}Cr -labeled B10.D2 fibroblasts as targets. Target cells were tested in

the absence of antigen, in the presence of Flu 147-155 peptide or following infection with influenza PR8 virus.

Representative results obtained from one of four independently run experiments are summarized in the following table.

5

CTL Immunogenicity of Various Modifications and Formulations of PR8-NP 148-155

Peptide	Formulation					
	Saline		Alum		IFA	
	0.01 ^a	0.1	0.01	0.1	0.01	0.1
932.01	-b	-	-	-	+	++
932.07	++	+	-	-	-	-
932.01 + 577.01	-	++	-	-	+++	++
932.07 + 577.01	+	-	-	-	-	±
932.02	-	-	-	+++	+++	+++
932.04	+++	+++	+++	+++	+++	+++
932.03	-	-	-	±	+++	++
932.05	+++	+++	+++	+++	+++	+++

25 a = Dose (μ M/mouse)

25 b = CTL immunogenicity of various modifications and formulations of NP 148-155 (nucleoprotein of PR8 influenza virus). Each symbol represents the result obtained from 30 spleen cells derived from a single Balb/c mouse and reflects the effector to target ratio (E:T) required to induce 40% 35 antigen specific lysis of ^{51}Cr labeled B10D2 target cells in the presence of NP₁₄₈₋₁₅₅ peptide; +++ E:T below 10:1; ++ E:T between 10:1 and 30:1; + E:T greater than 30:1; - not achieved 35 at any E:T tested.

Thus, the results were as follows:

40 IFA formulation: The HTL-CTL linked peptides either lipidated (i.e., 932.04 and 932.05) or unlipidated (932.02 and 932.03) were all very active, inducing good CTL activity in all animals at both injection doses. The mixture of HTL (577.01) and CTL (932.01) peptides also induced CTL activity in all animals injected. The CTL peptide (932.01) demonstrated good activity at the 100 nmoles dose, however, only one out of four animals responded at the 10 nmoles dose. The lipidated CTL peptide (932.07) was completely inactive but some activity, 45

albeit low, was observed when peptide 932.07 was mixed with the HTL peptide (577.01).

Saline formulation: The PAM₂-HTL-CTL linked peptides (932.04 and 932.05) induced good CTL activity in all animals injected and were far superior to all other peptide or peptide combinations tested. The unlipidated versions of those peptides (932.02 and 932.03) were totally ineffective at the 10 nmoles dose and only marginally active at the 100 nmoles dose underlying the importance of peptide lipidation for priming activity of saline formulations. For the other peptide combinations tested lipidation appeared to affect activity in the opposite direction as it did in IFA in that the CTL peptide (932.01) was completely inactive but its lipidated version (932.07) induced CTL activity in some of the animals injected. The activity of both peptides improved when mixed with the HTL peptide.

Alum formulation: The results obtained were similar to the ones obtained with peptides formulated in saline with the exception of peptide 932.07 that was inactive when injected in alum.

Accordingly, the constructs ($(PAM)_2KSS-T$ helper-CTL and $(PAM)_2KSS-T$ helper-AAA-CTL were superior when injected in saline or Alum compared to all of the other combinations. The peptides T helper-CTL and T helper-AAA-CTL were superior to mixing the T helper + CTL (i.e., non-linked) and worked well in IFA, but not well in saline or Alum. Thus, for vaccine development, linking the $(PAM)_2KSS$ to a T helper peptide which is linked to the CTL peptide appears to be advantageous for inducing CTL immunity.

EXAMPLE 8

DEFINITION OF THE MINIMAL OPTIMAL SEQUENCE
WITH THE CTL PEPTIDE EPITOPE 799.09

Transgenic mice (A2-1/Kb) were primed with HBV virus in IFA substantially as described in Example II. Seven days after priming, splenocytes obtained from these animals were restimulated with syngeneic irradiated LPS blasts coated with peptide 799.09 (as described in Example I). After 6 cycles of restimulation with 799.09 coated cells (as described in Example II) the effector cells were cloned by limiting dilution using syngeneic irradiated LPS blasts coated with peptide 799.09 (.2x10⁶ cells/well of a 96 well plate) and media supplemented with 10% rat Con A supernatant. Two CTL lines were obtained, line 110 and 113 that killed JA2Kb target cells coated with peptide 799.09. These lines were tested on a panel of 799.09 N-terminus truncated peptides and overlapping 9mers and 10mers covering the entire 799.09 sequence. As shown in Fig. 13 panel A the minimal N-terminus truncated peptide recognized by line 113 and 110 were respectively peptides HBV env. 333-348 (923-09) and 335-348 (923.07). Fig. 13 panel B shows that none of the 9mers or 10mers were recognized by line 113 implicating a longer peptide as the minimal sequence required for recognition by this CTL line. The minimal sequence recognized by line 110 is represented by peptides HBV env. 333-341 (923-26) and HBV env 335-343 (923.22) indicating that possibly two distinct but overlapping peptides can serve as antigenic determinants for 799.09 specific CTL.

EXAMPLE 9

PRIMING OF PEPTIDE 934.05 ("CY-1899") IN TRANSGENIC MICE

This example discloses that peptide 934.02 (i.e., tetanus toxoid 830-843-AAA-HBcAg 18-27) when modified by linking (PAM)₂KSS to the tetanus toxoid end (resulting in "CY-1899") and formulated in DMSO/saline induced CTLs in transgenic mice.

5 Lipopeptides were prepared by coupling the appropriate fatty acid to the amino terminus of the resin bound peptide. A typical procedure was as follows: A dichloromethane solution of a 4 fold excess of a pre-formed symmetrical anhydride of the appropriate fatty acid was added to the resin and the mixture was allowed to react for 2 hrs. The resin was washed with dichloromethane and dried. The resin was then treated with trifluoroacetic acid in the presence of appropriate 10 scavengers [e.g. 5% (v/v) water] for 60 minutes at 20°C. After evaporation of excess trifluoroacetic acid, the crude peptide was washed with diethyl ether, dissolved in methanol and precipitated by the addition of water. The peptide was collected by filtration and dried.

15 Preparation of peptides for immunization: Peptides were routinely resuspended in DMSO at a concentration of 20 mg/ml. Before use, peptides were prepared at the required concentration by dilution in saline or the appropriate medium. For selected experiments, CY-1899 and 934.02 were also prepared as saline suspensions (in the complete absence of 20 DMSO).

Immunization procedures: Transgenic mice were primed subcutaneously (base of the tail) with 0.1 ml of the appropriate peptide formulated in saline, or DMSO/saline.

25 Media:

a. RPMI-1640 supplemented with 10% fetal calf serum (FCS) 2 mM Glutamine, 50 µg/ml Gentamicin and 5×10^{-5} 2-mercaptoethanol served as culture medium and will be referred to as R10 medium.

b. RPMI-1640 containing 25 mM HEPES buffer and 30 supplemented with 2% (FCS) was used as cell washing medium.

Cell lines:

Jurkat A2.1/K^b (5) is a stable transfectant of the human T cell leukemia line, Jurkat. Jurkat A2.1/K^b cells were routinely grown in R10 medium supplemented with 400 µg/ml of 35 G418.

LPS-activated lymphoblasts: Splenocytes obtained from A2.1/K^b transgenic mice were resuspended at a concentration of

1-1.5x10⁶/ml in R10 medium supplemented with 25 μ g/ml LPS and 7 μ g/ml dextran sulfate in 75 cm² tissue culture flasks.

After 72 hr at 37°C, the lymphoblasts were collected for use by centrifugation.

5 **Peptide coating of lymphoblasts:** Peptide coating of the LPS activated lymphoblasts was achieved by incubating 30x10⁶ irradiated (3000 rads) lymphoblasts with 100 μ g of peptide in 1 ml of R10 medium for 1 hr at 37°C. Cells were then washed once and resuspended in R10 medium at the desired 10 concentration.

15 **In vitro CTL activation:** One to four weeks after priming spleen cells (30x10⁶ cells/flask) were co-cultured at 37°C with syngeneic, irradiated (3000 rads), peptide coated lymphoblasts (10x10⁶ cells/flask) in 10 ml of R10 medium/T25 flask. After 6 days, the effector cells were harvested and assayed for cytotoxic activity.

20 **Assay for cytotoxic activity:** Target cells (1.0-1.5x10⁶) were incubated at 37°C in the presence of 200 μ l of sodium ⁵¹Cr chromate. After 60 minutes, cells were washed three times and resuspended in R10 medium. Peptide 875.15 was added where required at a concentration of 1 μ g/ml. For the assay, 10⁴ ⁵¹Cr-labeled target cells were added to different concentrations of effector cells (final volume of 200 μ l) in U-bottom 96-well plates. After a 6 hour incubation period at 37°C, a 0.1 ml aliquot of supernatant was removed from each well and radioactivity was determined in a Micromedic automatic gamma counter. The percent specific lysis was determined by the formula: percent specific release = 100x (experimental release - spontaneous release)/(maximum release - spontaneous release). For the purpose of easy comparison between separate CTL assays run under the same conditions, % ⁵¹Cr release data was expressed as lytic units/10⁶ cells. One lytic unit is arbitrarily defined as the number of effector cells required to achieve 30% lysis of 10,000 Jurkat A2.1/K^b target cells in a 6 hour ⁵¹Cr release assay. To obtain specific lytic units/10⁶, the lytic units/10⁶ obtained in the absence of peptide is subtracted from the lytic units/10⁶

obtained in the presence of peptide. For example, if 30% ^{51}Cr release is obtained at the E:T of 50:1 (i.e., 5×10^5 effector cells for 10,000 targets) in the absence of peptide and 5:1 (i.e., 5×10^4 effector cells for 10,000 targets) in the presence of peptide, the specific lytic units would be:
5 $(1 \times 10^6 + 5 \times 10^4) - (1 \times 10^6 + 5 \times 10^5) = 18\text{LU}/10^6$.

RESULTS:

10 The results indicated that CY 1899 (i.e., tetanus toxoid 830-843-AAA-HBcAg 18-27) formulated in DMSO/saline is a strong immunogenic preparation inducing a good CTL response in all animals injected (six out of six).

15 CY 1899 in saline (without prior solubilization induced a poor CTL response in that only one of six animals injected had detectable CTL activity.

20 Peptide 934.02 in saline induced a marginal CTL response in that only one of the four animals tested had detectable CTL activity.

25 No CTL activity was detected in any of the animals injected with peptide 934.02 in DMSO/saline.

30 CTL induced by CY-1899 were shown to be able to kill cells expressing endogenous HBc antigen.

EXAMPLE 10**THE EFFECT OF LIPIDATION OF T HELPER EPITOPE ON CTL INDUCTION**

This example discloses that the desired CTL activity is induced in the absence of adjuvant (IFA or Alum) by 30 lipidation of the T-Helper epitope where the T-Helper epitope and the CTL epitope are not linked.

The effect of lipidation of the HTL peptide epitope on the immunogenicity of PR8-NP 147-155 CTL peptide epitope was determined. Peptides used in this Example were as follows:

<u>ID#</u>	<u>Description</u>	<u>Sequence</u>	<u>Seq ID No.</u>	
932-01	CTL	TYQRTRALV (PR8-NP 147-155)	116	
932.07	(PAM) ₂ -CTL	(PAM) ₂ KSSTYQRTRALV	117	
577.01	HTL	ISQAVHAAHAEINE	98	
5	932.06	(PAM) ₂ -HTL	(PAM) ₂ KSSISQAVHAAHAEINE	123
	932.04 or	(PAM) ₂ -HTL-CTL	(PAM) ₂ KSSISQAVHAAHAEINETYQRTRALV	124

Balb/c mice were injected with the different combinations indicated above of HTL (100 nmoles/mouse) and CTL (10 nmoles/mouse) peptide epitope in saline. Four animals were injected with each different preparation. Ten days after immunization, splenocytes were stimulated in vitro with NP 147-155 peptide. CTL activity was assayed 6 days later using ⁵¹Cr-labeled B10.D2 fibroblasts as targets in the absence or presence of NP 147-155 peptide. The data are expressed in lytic units/10₆ cells. One lytic unit is arbitrarily defined as the number of lymphocytes required to achieve 30% lysis of 5000 B10.D2 ⁵¹Cr-labeled target cells within 6 hours, in the absence or presence of NP 147-155 peptide. (a) Each number represents the specific CTL activity (LU 30/10₆ cells obtained in the presence of NP 147-155-LU 30/10₆ cells obtained in the absence of NP 147-0155) from an individual mouse.

Effect of HTL peptide epitope and peptide
 liquidation on the immunogenicity of
 PR8-NP 147-155 CTL peptide epitope

	<u>Priming Peptide Cytel ID Number</u>	<u>Description</u>	<u>LU30 (Geometric Mean)</u>
5	932.01	CTL	0 (a) 0.2 0 0 (0.1x/+1.4)
10	932.01+ 577.01	CTL+HTL	0 0.3 0 0 (0.1x/+1.7)
15	932.07	(PAM) ₂ -CTL	0 0 0.5 0 (0.15x/+2.2)
20	932.07+ 577.01	(PAM) ₂ -CTL+HTL	1 1.1 12.4 0 (1.1x/+7.2)
25	932.01+ 932.06	CTL+(PAM) ₂ -HTL	9.3 74.1 1.7 69.5 (16.9x/+6.1)
30	932.07+ 932.06	(PAM) ₂ -CTL+(PAM) ₂ -HTL	2.5 1 1 11.7 (2.3x/+6.1)
35	932.04	(PAM) ₂ -HTL-CTL	4.7 2 21 1.2 (3.9x/+3.5)
40			
45			
50			

5 The results obtained indicate that, 1) unlipidated peptides (932.01 and 932.01 + 577.01) are ineffective at the concentrations tested when injected in saline; 2) the presence of both the HTL and the CTL peptide epitope and the lipidation of at least one peptide is necessary for CTL induction when the peptides are formulated in saline.

10 The preferred combination appeared to be the lipidated HTL peptides unlinked to the unlipidated CTL peptide. Thus, a titration of the CTL epitope and the lipidated HTL epitope in mixtures was performed (i.e., the titration of $(PAM)_2$ -HTL peptide epitope and CTL peptide epitope in mixtures).

15 Balb/c mice were injected with 10 nmoles of the linked $(PAM)_2$ -HTL-CTL peptide immunogen and with mixtures containing 0, 1, 10, or 100 nmoles CTL epitope (932.01) and 0, 1, 10, or 100 nmoles PAM-helper epitope (932.06) per mouse as indicated in the table. Four animals were injected with each different preparation. Fourteen days after immunization, splenocytes were removed and stimulated in vitro with the NP 20 147-155 peptide. CTL activity was assayed 6 days later using ^{51}Cr -labeled B10.D2 fibroblasts as targets. Target cells were 25 tested in the absence or presence of antigen (NP 147-155 peptide). The data are expressed in lytic units/ 10^6 cells. One lytic unit is arbitrarily defined as the number of 30 lymphocytes required to achieve 30% lysis of 5000 B10.D2 ^{51}Cr -labeled target cells within 6 hours, in the absence or presence of antigen (NP 147-155 peptide). (a) Each number represents the specific CTL activity (LU 30/ 10^6 cells; obtained in the presence of NP 147-155 - LU 30/ 10^6 cells obtained in the absence of NP 147 155) from an individual mouse.

Titration of $(PAM)_2$ -HTL peptide epitope and CTL peptide epitope contained in mixtures

5

		nmoles CTL epitope, 932.01			
		0	1	10	100
		LU 30	LU 30	LU 30	LU 30
10	nmoles $(PAM)_2$ -HTL epitope 932.06	Geo Mean	Geo Mean	Geo Mean	Geo Mean
15	0				3.8(a) 0.8 0.3 1.3 1.0x/+2.9
20	1	3.8 23.9 2.6 0.2 2.6x/+7.2	2.5 4.4 0.2 4.4 1.8x/+4.4	3 7.4 2.6 2.6 3.5x/+1.7	
25	10	>58 29.5 2.2 53.5 21.2x/+4.7	50 20.3 7.3 27.5 21.2x/+2.2	68 53 >64 >68 62.9x/+1.1	
30	100	1.5 0.8 0.7 0 0.5x/+3.2	26 61 63 >54 48.2x/+1.5	69 >58 >41 7.9 33.7x/+2.7	64 >64 73 62 65.6x/+1.1
40	(PAM) ₂ -HTL- CTL65 10 nmoles 1053.05	90 17.8 25.4 40.3x/+2.1			

5 The results obtained indicate that optimal CTL induction (i.e., comparable to that achieved by immunization with 10 nmoles of the linked immunogen 1053.05) is achieved with mixtures containing 100 nmoles of the 932.06 [(PAM)₂ HTL] peptide and 1, 10 or 100 nmoles of the 932.01 (CTL) peptide. In the presence of 10 nmoles of 932.06, optimal CTL induction is achieved by the mixture containing 100 nmoles of 932.01 10 while a slight decrease was observed in the mixtures containing either 10 or 1 nmoles of the CTL peptide.

15 **Lipidated T-Helper Epitopes with Multiple CTL Epitopes.**

By following the procedures described in this

15 Example 10, a composition of matter comprising of a lipidated HTL admixed with multiple CTL epitopes can be prepared. Optionally, the CTL epitopes can be packaged in different vials from the HTL epitope(s).

20

EXAMPLE 11
INDUCTION OF SPECIFIC CTL RESPONSE IN HUMANS

25

The human clinical trial for CY-1899 was set up as an IND Phase I dose escalation study (5, 50 and 500 µg) and was carried out in a single center as a randomized double-blind placebo controlled trial.

30

A total of 27 subjects were enrolled and divided

into 3 groups:

Group I: 3 subjects were injected with placebo and 6 subjects were injected with 5 µg of CY-1899;

Group II: 3 subjects were injected with placebo and 6 subjects were injected with 50 µg of CY-1899;

35 Group III: 3 subjects were injected with placebo and 6 subjects were injected with 500 µg of CY-1899.

After 5 weeks (G1 and GII) or 4 weeks (GIII) following the first injection, all subjects received a booster inoculation at the same dosage.

The endpoints measured in this study relate to the safety and tolerability of CY-1899 (also known as Theradigm-HBV) as well as its immunogenicity. Cellular immune responses to CY-1899 are an index of the intrinsic activity of this drug, and can therefore be viewed as a measure of biological efficacy. The following summarized the clinical and laboratory data relating to safety and efficacy endpoints.

Safety: Adverse events were observed with similar frequency in the placebo and drug treatment groups. All adverse events were judged to be mild in degree and completely reversible. No relationship between adverse events and dose level were found. The most common adverse events were headache (4 subjects) and skin reaction at the site of inoculation (3 subjects).

Evaluation of Vaccine Efficacy: For evaluation of vaccine efficacy subjects were bled before and after injection. Peripheral blood mononuclear cells were isolated from fresh heparinized blood by Ficoll-Hypaque density gradient centrifugation, aliquoted in freezing media and stored frozen. Samples were assayed for CTL and HTL activity.

Data: Injection of CY-1899 in normal volunteers resulted in induction of HBc18-27 specific CTL is disclosed in Figs. 14 and 15. The CTL response observed was dose dependent both in the proportion of subjections exhibiting a positive response as well as in the magnitude of the response obtained. The dose response effect is demonstrated in Fig. 16 where the mean peak CTL activity per each group of subjects after the first and second injections are shown.

The peptide-induced CTL responses were capable of killing cells expressing endogenous antigen (as disclosed in Fig. 17) validating the concept of peptide priming for induction of virus specific CTL.

The proliferative T cell response against the helper TT peptide among the subjects receiving the three doses of CY-

1899 correlates with their CTL responses (as disclosed in Fig. 18). The most striking T cell responses against the TT helper peptide were observed in individuals receiving the highest vaccine dose. In three out of four subjects in this dose group a strong T cell proliferative response against TT peptide was correlated with high levels of CTL induction following vaccination with CY-1899. The only instance where a strong CTL response was observed in the absence of helper T cell induction was in the case of an individual who demonstrated a late CTL response 14 days after boosting.

10

EXAMPLE 12
SPECIFIC CTL INDUCING VACCINE
FOR PREVENTING AND/OR TREATING HCV

15

By following the procedures disclosed in Examples 1-11 a therapeutic composition of matter useful for treating mammals with HCV infections by inducing specific CTLs can be made.

20

For example, following the procedures in Examples 1, and 2, or alternatively Example 2A, peptides suitable for inducing CTLs can be identified, for example, the following peptides:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HCV NS4	1807	LLFNILGGWV	10	125	3.5000
HCV CORE	178	LLALLSCLTV	10	126	0.6050
HCV NS4	1585	YLVAYQATV	9	127	0.2450
HCV NS1/ENV	725	FLLLADARV	9	128	0.2250
HCV NS4	1851	ILAGYGAGV	9	129	0.2150
HCV CORE	132	DLMGYIPLV	9	130	0.0835
HCV CORE	35	YLLPRRGPRL	10	131	0.0725
NS1/ENV2	686	ALSTGLIHL	9	132	0.0415
HCV CORE	178	LLALLSCLTI	10	133	0.0340
HCV NS5	2578	RLIVFPDLGV	10	134	0.0320
HCV NS5	2885	RLHGLSAFSL	10	135	0.0200
HCV NS4	1811	ILGGWVAAQL	10	136	0.0180
HCV ENV1	364	SMVGNWAKV	9	137	0.0155
HCV NS3	1131	YLVTRHADV	9	138	0.0109
HCV NS4	1666	VLAALAAAYCL	10	139	0.0106

20

Once identified, such desired peptides can be obtained either commercially or prepared following the procedures disclosed in Example 3.

25

The preferability of the identified peptides is elaborated by optimization of the configuration of the composition of matter (i.e., whether the T-Helper and CTL peptides are linked or unlinked, and whether the peptides are delivered in a saline, alum or IFA medium, lipidated T-Helper linked or unlinked to the CTL in saline, or linked and unlinked T-Helper with CTL in IFA).

30

By following the procedures disclosed above and in the preceding examples a vaccine capable of treating HCV can be obtained.

35

EXAMPLE 13
SPECIFIC CTL INDUCING VACCINE
FOR PREVENTING AND/OR TREATING MELANOMA

5 By following the procedures disclosed in Examples 1-10 a therapeutic composition of matter useful for treating mammals with melanomas by inducing specific CTLs is made.

10 For example, following the procedures in Examples 1, and 2, or alternatively Example 2A, peptides suitable for inducing CTLs are identified, for example, the following peptides:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
MAGE2	105	KMVELVHFL	9	140	0.5100
MAGE2	105	KMVELVHFL	10	141	0.2200
MAGE3	153	LVFGIELMEV	10	142	0.1100
MAGE1	278	KVLEYVIKV	9	143	0.0900
MAGE1	105	KVADLVGFLL	10	144	0.0560
MAGE3	105	KVAEFVHFL	9	145	0.0550
MAGE1	92	CILESLFRA	9	146	0.0460
MAGE1	264	FLWGPRALA	9	147	0.0420
MAGE1	200	VMIAMEGGHA	10	148	0.0360
MAGE1	38	LVLGTLLEEV	9	149	0.0320
MAGE1	301	ALREEEEgv	9	150	0.0210
MAGE1	270	ALAETSYVKV	10	151	0.0150
MAGE1	282	YVIKVSARV	9	152	0.0140
MAGE1	269	RALAETSYV	9	153	0.0100

30 The peptides can be obtained either commercially or prepared following the procedures disclosed in Example 3.

35 The preferability of the identified peptides is elaborated by optimization of the configuration of the

composition of matter (i.e., whether the T-Helper and CTL peptides are linked or unlinked, and whether the peptides are delivered in a saline, alum or IFA medium, lipidated T-Helper linked or unlinked to the CTL in saline, or linked and unlinked T-Helper with CTL in IFA).

5 By following the procedures disclosed above and in the preceding examples a vaccine capable of treating melanomas is obtained.

10

EXAMPLE 14
SPECIFIC CTL INDUCING VACCINE
FOR PREVENTING AND/OR TREATING HPV

15 By following the procedures disclosed in Examples 1-10 a therapeutic composition of matter useful for treating mammals with HPV infections by inducing specific CTLs is made.

20 For example, following the procedures in Examples 1, and 2, or alternatively Example 2A, peptides suitable for inducing CTLs are identified, for example, the following peptides:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HPV16 E7	82	LIMGTLGIV	9	65	0.0240
HPV16 E7	11	YMLDLQPET	9	66	0.1400
HPV16 E6	52	FAFRDLCIV	9	67	0.0570
HPV16 E7	86	TLGIVCPIC	9	68	0.0750
HPV16 E7	7	TLHEYMLDL	9	69	0.0070
HPV16 E7	85	GTLGIVCPI	9	70	0.0820
HPV16 E7	12	MLDLQPETT	9	71	0.0028
HPV16 E6	29	TIHDIILECV	10	72	0.0210

The peptides can be obtained either commercially or prepared following the procedures disclosed in Example 3.

The preferability of the identified peptides is elaborated by optimization of the configuration of the composition of matter (i.e., whether the T-Helper and CTL peptides are linked or unlinked, and whether the peptides are delivered in a saline, alum or IFA medium, lipidated T-Helper linked or unlinked to the CTL in saline, or linked and unlinked T-Helper with CTL in IFA).

By following the procedures disclosed above and in the preceding examples a vaccine capable of treating HPV is obtained.

15

EXAMPLE 15
SPECIFIC CTL INDUCING VACCINE
FOR PREVENTING AND/OR TREATING HIV

By following the procedures disclosed in Examples 1-10 a therapeutic composition of matter useful for treating humans with HIV infections by inducing specific CTLs is made.

For example, following the procedures in Examples 1, and 2, or alternatively Example 2A, peptides suitable for inducing CTLs are identified, for example, the following peptides:

SOURCE	POSITION	SEQUENCE	SIZE	SEQ. ID NO.	BINDING A2
HIV	367	VLAEAMSQV	9	73	0.1100
5	1496	LLWKGEGAVV	10	74	0.0360
HIV	1496	LLWKGEGAV	9	75	0.0230
HIV	1004	ILKEPVHGV	9	76	0.0190
HIV	1129	IVGAETFYV	9	77	0.0099
HIV	1129	IIGAETFYV	9	78	0.0260
10	2182	LWVTVYYGV	9	79	0.0014
HIV	2182	LMVTVYYGV	9	80	0.4400

15 The peptides are obtained either commercially or prepared following the procedures disclosed in Example 3.

20 The preferability of the identified peptides is elaborated by optimization of the configuration of the composition of matter (i.e., whether the T-Helper and CTL peptides are linked or unlinked, and whether the peptides are delivered in a saline, alum or IFA medium, lipidated T-Helper linked or unlinked to the CTL in saline, or linked and unlinked T-Helper with CTL in IFA).

25 By following the procedures disclosed above and in the preceding examples a vaccine capable of treating HIV is obtained.

30 From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

WHAT IS CLAIMED IS:

1 1. A composition for inducing a cytotoxic T
2 lymphocyte to an antigen in a mammal which comprises a peptide
3 that induces a CTL response to said antigen and a peptide that
4 induces a HTL response, wherein the HTL-inducing peptide is
5 conjugated to a lipid.

1 2. The composition of claim 1, wherein the HTL-
2 inducing peptide is linked to the CTL-inducing peptide.

1 3. The composition of claim 1, wherein the HTL-
2 inducing peptide is not linked to the CTL-inducing peptide.

1 4. The composition of claim 1, wherein the HTL-
2 inducing peptide is linked to the lipid by a spacer.

1 5. The composition of claim 4, wherein the spacer
2 molecule is Lys-Ser-Ser.

1 6. The composition of claim 1, wherein the lipid is
2 linked to the N-terminus of the HTL-inducing peptide.

1 7. The composition of claim 6, wherein the HTL-
2 inducing peptide is linked to the lipid by a spacer.

1 8. The composition of claim 2, wherein the HTL-
2 inducing peptide is linked at its C-terminal end to the CTL-
3 inducing peptide.

1 9. The composition of claim 2, wherein the CTL-
2 inducing peptide is linked to the HTL-inducing peptide by a
3 spacer molecule.

1 10. The composition of claim 9, wherein the spacer
2 molecule between the CTL-inducing peptide and the HTL-inducing
3 peptide is Ala-Ala-Ala.

1 11. The composition of claim 1, wherein the antigen
2 to which the cytotoxic T lymphocyte response is induced is
3 selected from a viral, bacterial, parasitic or tumor antigen.

1 12. The composition of claim 1, wherein the antigen
2 to which the cytotoxic T lymphocyte response is induced is a
3 viral antigen of hepatitis B, hepatitis C or human papilloma
4 virus.

1 13. The composition of claim 12, wherein the
2 antigen is hepatitis B core or envelope antigen.

1 14. The composition of claim 13, wherein the
2 hepatitis B core antigen is HBc18-27.

1 15. The composition of claim 1, wherein the CTL-
2 inducing peptide is from seven to fifteen residues.

1 16. The composition of claim 15, wherein the CTL-
2 inducing peptide is nine to eleven residues.

1 17. The composition of claim 1, further comprising
2 a physiologically suitable medium.

1 18. The composition of claim 17, wherein the
2 physiologically suitable medium is physiologic saline.

1 19. The composition of claim 1, further comprising
2 an adjuvant.

1 20. The composition of claim 19, wherein the
2 adjuvant is incomplete freunds adjuvant, alum or montanide.

1 21. The composition of claim 1, wherein the lipid
2 is modified.

1 22. The composition of claim 1, wherein the lipid
2 is a linear alkyl chain of 6-22 carbons.

1 23. The composition of claim 22, wherein the lipid
2 is a linear alkyl chain of 16 carbons.

1 24. The composition of claim 1, wherein the lipid
2 is comprised of palmitic acid attached to epsilon and alpha
3 amino groups of a Lys residue, wherein the Lys is linked to
4 the amino terminus of the HTL-inducing peptide by means of a
5 linker.

1 25. A method for inducing a cytotoxic T lymphocyte
2 response in a mammal against an antigen, comprising
3 administering to the mammal a peptide that induces a CTL
4 response to said antigen and a peptide that induces a HTL
5 response, wherein the HTL-inducing peptide is conjugated to a
6 lipid.

1 26. The method of claim 25, wherein the HTL-
2 inducing peptide is linked to the CTL-inducing peptide.

1 27. The method of claim 25, wherein the HTL-
2 inducing peptide is not linked to the CTL-inducing peptide.

1 28. The method of claim 27, wherein the HTL-
2 inducing peptide is administered concurrently with the CTL-
3 inducing peptide.

1 29. The method of claim 28, wherein the HTL-
2 inducing peptide is admixed with the CTL-inducing peptide.

1 30. The method of claim 25, wherein a composition
2 of the HTL-inducing peptide and the CTL-inducing peptide is
3 administered to the mammal in a regimen of two or more
4 administrations spaced a sufficient interval apart to optimize
5 development of a cytotoxic immune response to the antigen.

1 31. The method of claim 30, wherein the composition
2 of the HTL-inducing peptide and CTL-inducing peptide is
3 administered to the mammal in a second administration
4 approximately four weeks after the initial administration.

1 32. The method of claim 25, wherein the antigen to
2 which the cytotoxic T lymphocyte response is induced is
3 selected from a viral, bacterial, parasitic, or tumor antigen.

1 33. The method of claim 32, wherein the viral
2 antigen to which the cytotoxic T lymphocyte response is
3 induced is a hepatitis B core or envelope antigen.

1 34. The method of claim 33, wherein the antigen is
2 hepatitis B core antigen HBc18-27 and the mammal is a human of
3 the HLA-A2.1 histocompatibility type.

1 35. A method for treating or preventing in a mammal
2 a disease that is susceptible to treatment by a CTL response,
3 comprising administering to the mammal a peptide that induces
4 a CTL response to a CTL-inducing antigen associated with said
5 disease and a peptide that induces a HTL response, wherein the
6 HTL-inducing peptide is conjugated to a lipid.

1 36. The method of claim 35, wherein the disease is
2 selected from a viral, bacterial or parasitic infection.

1 37. The method according to claim 35, wherein the
2 disease is a tumor.

WO 95/22317

79

1 38. The method of claim 36, wherein the viral
2 infection is hepatitis B, hepatitis C or human papilloma
3 virus.

1 39. The method of claim 38, wherein the hepatitis B
2 antigen is core.

1 40. The method of claim 39, wherein the hepatitis B
2 core antigen is HBc18-27 and the mammal is a human of the HLA-
3 A2.1 histocompatibility type.

1 41. The method of claim 40, wherein the human has
2 chronic hepatitis B infection.

1 42. The method of claim 40, wherein the human has
2 acute hepatitis B infection.

1 43. The method of claim 35, wherein a compositions
2 of the CTL inducing peptide associated with said disease and
3 the lipidated HTL-inducing peptide is administered
4 prophylactically.

1 44. A method for inducing a cytotoxic T lymphocyte
2 response in a human against an antigen of interest, comprising
3 administering a composition which comprises a peptide that
4 induces a CTL response to said antigen and an adjuvant.

1 45. The method of claim 44, further comprising
2 administering a peptide that induces a HTL response.

1 46. The method of claim 45, wherein the HTL
2 inducing peptide is linked to the CTL inducing peptide.

1 47. A method for inducing a cytotoxic T lymphocyte
2 response in a human against an antigen of interest, comprising
3 administering a composition which comprises a peptide that
4 induces a CTL response to said antigen and a peptide that
5 induces a HTL response, wherein the CTL inducing and/or HTL
6 inducing peptide is lipidated.

1 48. The method of claim 47, wherein the CTL and HTL
2 inducing peptides are linked.

1 49. The method of claim 48, wherein the HTL
2 inducing peptide is lipidated.

1 50. The method of claim 47, wherein the HTL
2 inducing peptide is lipidated and the composition comprises a
3 cocktail of at least two CTL inducing peptides.

1 51. A method for inducing a cytotoxic T lymphocyte
2 response in a human against an antigen of interest, comprising
3 administering a composition which comprises a peptide that
4 induces a CTL response to said antigen and a peptide that
5 induces a HTL response, wherein the CTL inducing and/or HTL
6 inducing peptide is lipidated.

1 52. The method of claim 51, wherein the antigen to
2 which the CTL response is induced is selected from a viral,
3 bacterial, parasitic or tumor antigen.

1 53. The method of claim 52, wherein the antigen to
2 which the CTL response is induced is a viral antigen.

1 54. The method of claim 53, wherein the viral
2 antigen is a hepatitis B antigen.

1 55. A pharmaceutical composition for the treatment
2 of hepatitis B infection which comprises a peptide that
3 induces a CTL response to hepatitis B and a peptide that
4 induces a HTL response, wherein the HTL-inducing peptide is
5 conjugated to a lipid, and a pharmaceutically acceptable
6 carrier.

1 56. The pharmaceutical composition of claim 55,
2 wherein the CTL inducing peptide is HBc18-27.

1 57. The pharmaceutical composition of claim 55,
2 wherein the lipid is linked to the N terminus of the HTL-
3 inducing peptide.

1 58. The pharmaceutical composition of claim 57,
2 wherein the HTL-inducing peptide is admixed with the CTL-
3 inducing peptide.

1 59. The pharmaceutical composition of claim 57,
2 wherein the HTL-inducing peptide is linked at its carboxy
3 terminal end to the CTL inducing peptide.

1 60. The pharmaceutical composition of claim 55,
2 wherein the carrier is a liposome.

1 61. The pharmaceutical composition of claim 55,
2 further comprising an adjuvant.

1 62. The pharmaceutical composition of claim 61,
2 wherein the adjuvant is selected from incomplete Freund's
3 adjuvant, alum or montanide.

WO 95/22317

1 / 23




FIG. 1a




FIG. 1b




FIG. 1c

2 / 23




FIG. 1d




FIG. 1e




FIG. 1f

3 / 23




FIG. 1g




FIG. 1h




FIG. 2i

4 / 23




FIG. 2j




FIG. 2k




FIG. 2l

5 / 23




FIG. 2m




FIG. 2n




FIG. 2o

6 / 23




FIG. 2p




FIG. 3a




FIG. 3b

7 / 23




FIG. 3c




FIG. 3d




FIG. 3e

8 / 23




FIG. 3f




FIG. 3g




FIG. 3h

9 / 23




FIG. 3i




FIG. 3j




FIG. 3k

10 / 23




FIG. 3/




FIG. 4a




FIG. 4b

10 / 23




FIG. 3/




FIG. 4a




FIG. 4b

12 / 23




FIG. 4f




FIG. 4g




FIG. 4h

13 / 23




FIG. 4i




FIG. 4j




FIG. 4k

14 / 23




FIG. 4




FIG. 5




FIG. 6

15 / 23




FIG. 7




FIG. 8




FIG. 9

16 / 23




FIG. 10a




FIG. 10b




FIG. 11





FIG. 12



SUBSTITUTE SHEET (RULE 26)




FIG. 14B.




FIG. 14D.




FIG. 14A.




FIG. 14C.

20 / 23




FIG. 15B.




FIG. 15A.




FIG. 15C.




FIG. 15D.




FIG. 16.

22 / 23




FIG. 17A.




FIG. 17B.

23 / 23




FIG. 18A.




FIG. 18B.




FIG. 18C.

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02121

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 9/127, 39/002, 39/02, 39/12, 39/29, 39/295, 39/385

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 189.1, 194.1, 201.1, 202.1, 203.1, 227.1, 234.1, 265.1, 227.1, 450

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CA, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nature, Volume 342, issued 30 November 1989, K. Deres et al, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine", pages 561-564, see pages 561 and 562.	1-62
X	WO, A, 93/03764 (VITIELLO ET AL) 04 March 1993, see pages 8-11, 15, 19-21, 23, 24 and 27-29.	1-62
X	US, A, 5,128,319 (ARLINGHAUS) 07 July 1992, columns 3-4.	44 1-43,45-62
Y		

Further documents are listed in the continuation of Box C.

See patent family annex.

•	Special categories of cited documents:	
•A	document defining the general state of the art which is not considered to be of particular relevance	“T”
•B	earlier document published on or after the international filing date	“X”
•L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y”
•O	document referring to an oral disclosure, use, exhibition or other means	“Z”
•P	document published prior to the international filing date but later than the priority date claimed	document member of the same patent family

Date of the actual completion of the international search

12 MAY 1995

Date of mailing of the international search report

22 MAY 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faximile No. (703) 305-3230

Authorized officer

KAY K. KIM, PH.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02121

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. Exp. Med., Volume 165, issued February 1987, E. Watari et al, "A SYNTHETIC PEPTIDE INDUCES LONG-TERM PROTECTION FROM LETHAL INFECTION WITH HERPES SIMPLEX VIRUS 2", pages 459-470, see page 459.	1-62
Y	J. Exp. Med., Volume 174, issued December 1991, A. Penna et al, "Cytotoxic T Lymphocytes Recognize an HLA-A2-restricted Epitope within the Hépatitis B Virus Nucleocapsid Antigen", pages 1565-1570, see page 1565.	1-62
Y	US, A, 5,013,548 (HAYNES ET AL) 07 May 1991, columns 5-6.	1-62
Y	Proc. Natl. Acad. Sci., USA, Volume 88, issued March 1991, W. M. Kast et al, "Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide", pages 2283-2287, see page 2283.	1-62
Y	US, A, 4,599,230 (MILICH ET AL) 08 July 1986, columns 23-26.	1-62
Y	EP, A, 0,429,816 (ETLINGER) 05 June 1991, abstract and page 3.	1-62

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/02121

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/184.1, 189.1, 194.1, 201.1, 202.1, 203.1, 227.1, 234.1, 265.1, 227.1, 450

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.